# 2026年1月16日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. KMT2A是IDH突变胶质瘤发生过程中恶性转化的先决条件。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41537229)
**期刊：** Neuro-oncology
**PMID：** 41537229
**DOI：** 10.1093/neuonc/noag006

### 第一部分 原文与翻译

**英文原标题：** KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis.

> **英文摘要：**
> BACKGROUND: IDH1R132H is the defining mutation of low-grade gliomas (LGGs), inflicting broad epigenetic rewiring that leads to malignant transformation. Recent studies demonstrated that cell fate change from astrocyte to LGG is accompanied by redistribution of H3K4 methylation. By modulating H3K4-methyltransferase KMT2A in a conditionally IDH1R132H-expressing human astrocyte model system, we sought to define requirements of IDH1R132H dependent gliomagenesis and identify novel therapeutic targets. METHODS: Using KMT2A inhibitor MM-102, we targeted H3K4me3 in IDH1R132H -expressing astrocytes, profiling L1CAM expression, proliferation, clonogenicity, invasion and migration, transcriptional and translational changes. Findings were validated in patient-derived IDH1R132H glioma lines with shRNA-mediated knockdown. Epigenetic transformation was characterized with CUT&Tag and MethylationEPIC. Downstream targets were assessed utilizing siRNAs. RESULTS: KMT2A inhibition significantly decreased L1CAM expression and led to broad transcriptional downregulation, including LGG marker genes. Analyses of transcriptomics and proteomics pointed to altered lipid metabolism and migratory capacity. Phenotypic characterization showed impaired invasion, migration and proliferation. We observed significantly reduced deposition of H3K4me3 at promoters of DEGs and enhanced global DNA methylation. We identified SCD as putative KMT2A-dependent effector whose knockdown reduced clonogenicity. In patient-derived models, KMT2A suppression impaired viability and spheroid growth in vitro; however, in an orthotopic TS603 model, knockdown shortened survival, indicating stage- and context-dependent effects. CONCLUSIONS: Disrupting KMT2A-mediated H3K4me3 reshapes the epigenome and attenuates LGG-relevant programs and phenotypes in vitro, supporting a strong role in tumor initiation. In vivo, the TS603 survival result highlights context-dependent maintenance and motivates cautious, microenvironment-aware therapeutic exploration of the KMT2A axis and downstream targets such as SCD.

> **中文摘要：**
> 背景：IDH1R132H是低级别胶质瘤（LGGs）的标志性突变，它引发广泛的表观遗传重编程，从而导致恶性转化。近期研究表明，从星形胶质细胞到LGG的细胞命运转变伴随着H3K4甲基化的重新分布。通过在条件性表达IDH1R132H的人星形胶质细胞模型系统中调控H3K4甲基转移酶KMT2A，我们试图明确IDH1R132H依赖性胶质瘤发生所需的条件，并识别新的治疗靶点。方法：使用KMT2A抑制剂MM-102，我们靶向抑制表达IDH1R132H的星形胶质细胞中的H3K4me3，并分析了L1CAM表达、增殖、克隆形成能力、侵袭和迁移能力，以及转录组和翻译组的变化。研究结果在通过shRNA介导敲低的患者来源IDH1R132H胶质瘤细胞系中进行了验证。使用CUT&Tag和MethylationEPIC技术表征了表观遗传转变。利用siRNA评估了下游靶点。结果：抑制KMT2A显著降低了L1CAM的表达，并导致了广泛的转录下调，包括LGG标志基因的下调。转录组学和蛋白质组学分析表明脂质代谢和迁移能力发生了改变。表型特征分析显示侵袭、迁移和增殖能力受损。我们观察到差异表达基因（DEGs）启动子处的H3K4me3沉积显著减少，以及整体DNA甲基化增强。我们确定SCD为假定的KMT2A依赖性效应因子，其敲低可降低克隆形成能力。在患者来源模型中，抑制KMT2A在体外损害了细胞活力和球体生长；然而，在原位TS603模型中，敲低KMT2A缩短了生存期，表明其作用具有阶段和背景依赖性。结论：破坏KMT2A介导的H3K4me3重塑了表观基因组，并在体外减弱了与LGG相关的程序及表型，支持了其在肿瘤起始中的重要作用。在体内，TS603模型的生存结果突显了其背景依赖性的维持功能，并促使我们以谨慎的态度，结合对微环境的考量，探索靶向KMT2A轴及其下游靶点（如SCD）的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明表观遗传调控因子KMT2A在IDH突变胶质瘤发生中的关键作用。通过在人星形胶质细胞模型和患者来源细胞系中结合药理学抑制与基因敲低，并整合多组学（转录组、蛋白质组、CUT&Tag、DNA甲基化）与表型分析，系统证明了KMT2A驱动的H3K4me3修饰是IDH1R132H诱导的恶性转化所必需的，并发现SCD等下游效应因子。其创新性在于将表观遗传调控与代谢重编程（脂质代谢）联系起来，并揭示了KMT2A功能具有肿瘤阶段和微环境背景依赖性，这为靶向治疗提供了新思路，但也提示了直接抑制该通路在特定情况下的潜在风险，是未来转化研究需审慎考虑的重要局限性。

---

## 2. 一种用于预测生殖毒性的、模拟三维多细胞复杂性和月经周期性的生物标志物驱动的卵巢-子宫内膜器官芯片。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41537195)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41537195
**DOI：** 10.1002/advs.202511098

### 第一部分 原文与翻译

**英文原标题：** A Biomarker-Driven Ovary-Endometrium Organ-on-a-Chip Mimicking 3D Multicellular Complexity and Menstrual Cyclicity for Predicting Reproductive Toxicity.

> **英文摘要：**
> Reliable prediction of reproductive toxicity remains a critical challenge in drug development and environmental safety. Here, a biomarker-integrated, fluorescent reporter-based reproductive organ-on-a-chip platform that recapitulates the multicellular composition, 3D architecture, endocrine signaling, and cyclic dynamics of the human menstrual cycle, is presented. The system is constructed using primary human theca, granulosa, endometrial stromal and stem cells, vascular endothelial cells, uterine macrophages, and myometrial smooth muscle cells, compartmentalized within collagen-hyaluronic acid hydrogels. Early-response toxicity biomarkers-ANGPTL4 (ovary) and SERPINB2 (endometrium)-are genetically linked to mCherry or GFP fluorescent reporters, enabling real-time, cell类型特异性 visualization of toxicant-induced stress. Transcriptomic profiling, KEGG pathway enrichment, and gene knockdown studies confirm ANGPTL4 and SERPINB2 as functional mediators of toxic injury, not just passive indicators. Upon exposure to dioxin and other reproductive toxicants, the platform shows strong, region-specific fluorescent responses that preceded changes detected by conventional cytotoxicity assays. This system demonstrates high sensitivity, temporal precision, and mechanistic insight, offering a scalable and physiologically relevant tool for high-content reproductive toxicology screening. Furthermore, it supports endocrine crosstalk between the ovary and uterus, and dynamic responses across the menstrual cycle, enabling future applications in personalized toxicity prediction and preclinical safety evaluation.

> **中文摘要：**
> 生殖毒性的可靠预测仍然是药物开发和环境安全领域的一个关键挑战。本文介绍了一种基于生物标志物整合、荧光报告基因的生殖器官芯片平台，该平台重现了人类月经周期的多细胞组成、三维结构、内分泌信号传导和周期性动态。该系统使用原代人卵泡膜细胞、颗粒细胞、子宫内膜基质和干细胞、血管内皮细胞、子宫巨噬细胞和子宫肌层平滑肌细胞构建，这些细胞被分隔在胶原-透明质酸水凝胶中。早期反应毒性生物标志物——ANGPTL4（卵巢）和SERPINB2（子宫内膜）——被基因连接到mCherry或GFP荧光报告基因上，从而能够实时、细胞类型特异性地可视化毒物诱导的应激。转录组分析、KEGG通路富集和基因敲低研究证实，ANGPTL4和SERPINB2是毒性损伤的功能性介质，而不仅仅是被动指标。在暴露于二噁英和其他生殖毒物时，该平台显示出强烈的、区域特异性的荧光反应，这些反应早于传统细胞毒性检测方法所检测到的变化。该系统表现出高灵敏度、时间精确性和机制洞察力，为高通量生殖毒理学筛选提供了一个可扩展且生理相关的工具。此外，它支持卵巢和子宫之间的内分泌串扰，以及整个月经周期的动态响应，为未来在个性化毒性预测和临床前安全性评估中的应用奠定了基础。

### 第二部分 AI 大师评价

本研究旨在解决生殖毒性预测的难题，通过构建一个高度仿生的卵巢-子宫内膜器官芯片模型。其核心创新在于整合了原代多细胞类型、三维微环境、月经周期动态，并巧妙地将早期毒性生物标志物ANGPTL4和SERPINB2与荧光报告基因耦合，实现了对毒物应激的实时、细胞类型特异性可视化监测。研究发现，该平台对二噁英等毒物的响应比传统方法更早、更灵敏，且通过组学分析证实了所选生物标志物的功能性角色，提供了机制层面的见解。该模型为高通量、高内涵的生殖毒理学筛选及个性化风险评估提供了强大的工具，但其局限性可能在于模型的长期稳定性、更广泛毒物库的验证，以及将体外发现外推至复杂体内环境的不确定性。

---

## 3. 用于急性肾损伤诊疗一体化的精密工程化银单原子碳点纳米酶

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41536235)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41536235
**DOI：** 10.1002/advs.202519393

### 第一部分 原文与翻译

**英文原标题：** Precision-Engineered Silver Single-Atom Carbon Dot Nanozymes for Theranostic Management of Acute Kidney Injury.

> **英文摘要：**
> Overproduction of reactive oxygen species (ROS) is a key pathogenic feature in acute kidney injury (AKI), leading to rapid decline in renal function with high mortality rates that call for effective antioxidant therapies. Herein, we present triphenylphosphonium-functionalized carbon dots supported by single-atom silver (T-Ag-CDs) that integrate fluorescent antioxidant nanozymes for the accurate ROS scavenging and real-time bioimaging of AKI. By anchoring silver in single-atom and sub-nanocluster states on a carbon dot matrix, T-Ag-CDs exhibit exceptional superoxide dismutase (SOD)- and glutathione peroxidase (GPx)-like activities, surpassing traditional nanozymes in ROS neutralization efficiency. Density functional theory (DFT) calculations disclose a low-energy reaction pathway common to both nitrogen-doped carbon dots (N-CDs) and Ag-CDs, clarifying the mechanism behind their dual SOD- and GPx-mimetic activities. The biocompatible N-CDs platform guarantees the stability, minimizes Ag-associated toxicity, and enhances catalytic performance through synergistic Ag-CD interactions. Targeting mitochondria through triphenylphosphonium functionalization facilitates site-specific antioxidant protection, demonstrating robust therapeutic efficacy in a cisplatin-induced AKI mouse model. Additionally, the intrinsic fluorescence of T-Ag-CDs facilitates non-invasive monitoring of biodistribution and renal accumulation, promotes the recovery of damaged kidney tissue, alleviates oxidative stress and post-cure assessment, and offers a self-reported theranostic platform, while also aiming to improve its clinical application.

> **中文摘要：**
> 活性氧（ROS）的过度产生是急性肾损伤（AKI）的一个关键致病特征，导致肾功能迅速下降和高死亡率，因此需要有效的抗氧化疗法。本文中，我们提出了由单原子银支撑的三苯基膦功能化碳点（T-Ag-CDs），它集成了荧光抗氧化纳米酶，用于AKI的精准ROS清除和实时生物成像。通过将银以单原子和亚纳米团簇状态锚定在碳点基质上，T-Ag-CDs表现出卓越的超氧化物歧化酶（SOD）和谷胱甘肽过氧化物酶（GPx）样活性，在ROS中和效率上超越了传统纳米酶。密度泛函理论（DFT）计算揭示了一条氮掺杂碳点（N-CDs）和Ag-CDs共有的低能反应路径，阐明了其兼具SOD和GPx模拟活性的机制。生物相容性的N-CDs平台保证了稳定性，最小化了银相关的毒性，并通过银-碳点协同相互作用增强了催化性能。通过三苯基膦功能化靶向线粒体，促进了位点特异性的抗氧化保护，在顺铂诱导的AKI小鼠模型中显示出强大的治疗效果。此外，T-Ag-CDs的固有荧光特性便于无创监测其生物分布和肾脏蓄积，促进受损肾组织的恢复，缓解氧化应激并用于治疗后评估，提供了一个自我报告的诊疗一体化平台，同时也旨在改善其临床应用。

### 第二部分 AI 大师评价

本研究旨在开发一种针对急性肾损伤（AKI）氧化应激的诊疗一体化纳米平台。其核心创新在于构建了负载单原子/亚纳米团簇银的三苯基膦功能化碳点（T-Ag-CDs），该材料兼具卓越的SOD/GPx双酶模拟活性与荧光成像能力。通过DFT计算揭示了催化机制，并利用线粒体靶向实现了精准抗氧化治疗，在动物模型中验证了疗效。该工作将精准催化、靶向递送与实时成像相结合，为AKI提供了有前景的诊疗新策略，但其临床转化潜力仍需进一步的生物安全性和长期疗效评估。

---

## 4. 腹腔干动脉狭窄对接受胰十二指肠切除术和全胰切除术患者的影响：一项国际多中心研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535998)
**期刊：** Annals of surgery
**PMID：** 41535998
**DOI：** 10.1097/SLA.0000000000007011

### 第一部分 原文与翻译

**英文原标题：** Impact of Celiac Axis Stenosis in Patients Undergoing Pancreatoduodenectomy and Total Pancreatectomy: International Multicenter Study.

> **英文摘要：**
> OBJECTIVE: To assess the impact of celiac axis stenosis (CAS) on postoperative outcome after pancreatoduodenectomy (PD) and total pancreatectomy (TP), and to describe treatment strategies based on CAS severity and etiology. SUMMARY BACKGROUND DATA: Asymptomatic CAS may compromise hepatic and gastric perfusion after PD and TP, potentially increasing morbidity. The role of preoperative CAS detection and treatment remains unknown. METHODS: International retrospective study at four high-volume centers in four countries (2018-2024). All preoperative CT imaging was re-assessed. CAS >50% stenosis was graded as B/C and considered clinically relevant. Etiology was classified as atherosclerotic, median arcuate ligament [MAL]-related, or mixed. Outcome was associated with CAS severity, etiology, and treatment. Standardized management protocols per center were identified. RESULTS: Among 1,698 patients undergoing PD and TP, CAS was identified in 16% (n=279). CAS grade B/C (6.5%, n=111) was independently associated with severe complications (OR 2.20, P<0.001), bile leak (OR 2.67, P=0.007), liver perfusion failure (OR 2.60, P<0.001), and gastric ischemia (OR 11.29, P<0.001). Outcomes differed by etiology: atherosclerotic CAS was associated with higher bile leak rate (22.7% vs. 5.7%; P=0.018) than MAL-related CAS. Centers with standardized protocols identified and treated CAS more frequently. CONCLUSIONS: CAS grade B/C is an underrecognized yet potentially modifiable risk factor for severe complications after PD and TP. Preoperative identification of CAS grade B/C, including etiology, may allow targeted intervention but larger studies are required.

> **中文摘要：**
> 目的：评估腹腔干动脉狭窄（CAS）对胰十二指肠切除术（PD）和全胰切除术（TP）术后结局的影响，并根据CAS的严重程度和病因描述治疗策略。背景资料摘要：无症状的CAS可能在PD和TP后损害肝脏和胃的灌注，从而可能增加并发症发生率。术前CAS检测和治疗的作用尚不清楚。方法：在四个国家的四个高手术量中心进行的国际回顾性研究（2018-2024年）。所有术前CT影像均被重新评估。狭窄>50%的CAS被分级为B/C级，并被视为具有临床相关性。病因被分类为动脉粥样硬化性、正中弓状韧带（MAL）相关或混合性。结局与CAS的严重程度、病因和治疗相关。识别了各中心的标准化管理方案。结果：在接受PD和TP的1,698名患者中，16%（n=279）发现了CAS。B/C级CAS（6.5%，n=111）与严重并发症（OR 2.20，P<0.001）、胆漏（OR 2.67，P=0.007）、肝脏灌注衰竭（OR 2.60，P<0.001）和胃缺血（OR 11.29，P<0.001）独立相关。结局因病因而异：与MAL相关的CAS相比，动脉粥样硬化性CAS与更高的胆漏率相关（22.7% vs. 5.7%；P=0.018）。拥有标准化方案的中心更频繁地识别并治疗了CAS。结论：B/C级CAS是PD和TP术后严重并发症的一个未被充分认识但可能可改变的风险因素。术前识别B/C级CAS，包括其病因，可能有助于进行针对性干预，但需要更大规模的研究。

### 第二部分 AI 大师评价

本研究通过国际多中心回顾性分析，明确了腹腔干动脉狭窄（CAS）是胰腺大手术后严重并发症的重要可干预风险因素。其创新性在于首次大规模量化了不同病因（动脉粥样硬化性与正中弓状韧带压迫性）CAS对术后特定并发症（如胆漏）影响的差异，并强调了建立标准化术前识别与处理流程的重要性。然而，作为回顾性研究，其结论存在固有局限性，且文中提到的针对性干预措施的具体效果仍需前瞻性研究进一步验证。

---

## 5. 铁死亡与转移：分子检查点、微环境动态与治疗机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535945)
**期刊：** Molecular cancer
**PMID：** 41535945
**DOI：** 10.1186/s12943-025-02544-y

### 第一部分 原文与翻译

**英文原标题：** Ferroptosis and metastasis: molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities.

> **英文摘要：**
> Ferroptosis is a non-apoptotic form of regulated cell death driven by iron dependent lipid peroxidation. It sits at the intersection of several hallmarks of metastatic cancer, including metabolic rewiring, membrane remodeling, epithelial mesenchymal plasticity, immune editing, and adaptation to distant niches. In this review, we integrate biochemical mechanisms with single cell, spatial, and in vivo data to map how ferroptotic pressure changes as tumor cells invade, travel through vessels, extravasate, enter dormancy, and re-awaken to form overt metastases. We highlight that these dynamics are strongly shaped by organ context. Lymph and adipose rich environments buffer lipid peroxidation and favor survival. In contrast, blood circulation increases oxidative load, and brain and liver niches impose distinct constraints on redox balance, iron handling, and lipid repair. We then examine how ferroptosis interfaces with the immune system. Ferroptotic stress can increase tumor antigenicity and danger signaling and thereby promote antitumor responses. The same stress, however, can reprogram monocytes, macrophages, and neutrophils, drive neutrophil extracellular trap formation, and support lipid exchange that weakens effector T cell function. This dual behavior helps explain why ferroptosis can restrict dissemination in some settings yet fuel pro-metastatic inflammation in others. On this mechanistic background, we evaluate therapeutic strategies that aim to exploit ferroptosis related vulnerabilities. These include inhibition of cystine supply or lipid repair pathways, radiosensitization regimens that increase lipid peroxidation, diet drug combinations that rewire sulfur and lipid metabolism, and nanoplatforms that co-deliver ferroptosis triggers with photo or sonodynamic therapies. Clinically, ferroptosis programs are increasingly linked to metastatic organotropism, responses to radiotherapy and immunotherapy, and patient survival, and they are beginning to guide biomarker development and early translational trials. We also discuss practical barriers, such as niche specific resistance circuits, constraints imposed by drug delivery and toxicity, and the scarcity of robust patient level ferroptosis readouts. Methodological advances - including compartment resolved reporters, spatial lipidomics, and circulating signatures of lipid damage - may help address these gaps. Overall, viewing metastasis through the ferroptosis lens reveals actionable vulnerabilities and supports rational radio immunometabolic combinations aimed at durable control of metastatic disease.

> **中文摘要：**
> 铁死亡是一种由铁依赖性脂质过氧化驱动的非凋亡性调节性细胞死亡。它位于转移性癌症多个特征的交叉点，包括代谢重编程、膜重塑、上皮间质可塑性、免疫编辑以及对远处生态位的适应。在这篇综述中，我们将生化机制与单细胞、空间和体内数据相结合，描绘了铁死亡压力如何随着肿瘤细胞侵袭、在血管中迁移、外渗、进入休眠和重新激活形成明显转移而变化。我们强调这些动态在很大程度上受器官环境的影响。富含淋巴和脂肪的环境能缓冲脂质过氧化并有利于生存。相比之下，血液循环增加了氧化负荷，而大脑和肝脏生态位对氧化还原平衡、铁处理和脂质修复施加了独特的限制。接着，我们探讨了铁死亡如何与免疫系统相互作用。铁死亡应激可以增加肿瘤抗原性和危险信号，从而促进抗肿瘤反应。然而，同样的应激可以重编程单核细胞、巨噬细胞和中性粒细胞，驱动中性粒细胞胞外陷阱形成，并支持削弱效应T细胞功能的脂质交换。这种双重行为有助于解释为何铁死亡在某些情况下能限制播散，而在另一些情况下却助长促转移性炎症。在此机制背景下，我们评估了旨在利用铁死亡相关脆弱性的治疗策略。这些策略包括抑制胱氨酸供应或脂质修复通路、增加脂质过氧化的放射增敏方案、重编程硫和脂质代谢的饮食药物组合，以及共同递送铁死亡触发剂与光或声动力疗法的纳米平台。临床上，铁死亡程序与转移器官趋向性、对放疗和免疫治疗的反应以及患者生存率之间的联系日益紧密，并开始指导生物标志物开发和早期转化试验。我们还讨论了实际障碍，例如生态位特异性耐药回路、药物递送和毒性带来的限制，以及缺乏稳健的患者层面铁死亡读数。方法学上的进步——包括区室分辨的报告系统、空间脂质组学和脂质损伤的循环标志物——可能有助于解决这些差距。总体而言，通过铁死亡的视角审视转移，揭示了可操作的脆弱性，并支持旨在持久控制转移性疾病的合理放射免疫代谢联合疗法。

### 第二部分 AI 大师评价

该综述的核心目的是系统阐述铁死亡在肿瘤转移全过程中的动态作用及其治疗潜力。方法上，作者整合了生化机制与多组学及体内数据，构建了转移级联反应中的铁死亡压力图谱。主要发现包括：铁死亡压力受器官微环境（如淋巴/脂肪、血液、脑/肝）的强烈调控，并与免疫系统呈现促进抗肿瘤或促转移的双重交互作用。创新性在于将铁死亡这一基础细胞死亡机制置于转移的时空动态和器官特异性背景下进行全景式解析，并前瞻性地提出了多种靶向策略。局限性在于文中指出的临床转化障碍，如缺乏稳健的患者层面铁死亡读数、生态位特异性耐药以及递送与毒性挑战，这些是未来研究需要突破的关键点。

---

## 6. 肿瘤学中的肠道菌群失调：免疫抵抗的风险因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535719)
**期刊：** Cell research
**PMID：** 41535719
**DOI：** 10.1038/s41422-025-01212-6

### 第一部分 原文与翻译

**英文原标题：** Gut dysbiosis in oncology: a risk factor for immunoresistance.

> **英文摘要：**
> The gut microbiome is recognized as a determinant of response to immune checkpoint inhibitor (ICI) therapies in cancer. However, the clinical translation of microbiome science has been hampered by inconsistent definitions of dysbiosis, inadequate biomarker frameworks, and limited mechanistic understanding. In this review, we synthesize the current state of knowledge on how gut microbial composition and function influence ICI efficacy, highlighting both correlative and causal evidence. We discuss computational approaches based on α-diversity or taxonomic abundance and argue for more functionally and clinically informative models, such as the topological score (TOPOSCORE) and other dysbiosis indices derived from machine learning. Using retrospective analyses of metagenomic datasets from thousands of patients and healthy controls, we examine microbial patterns that distinguish responders from non-responders. We also explore how dysbiosis perturbs immunoregulatory pathways, including bile acid metabolism, gut permeability, and mucosal immunomodulation. Finally, we assess emerging therapeutic strategies aimed at correcting microbiome dysfunction - including dietary modification, bacterial consortia, and fecal microbiota transplantation - and describe how they are being deployed in multiple clinical trials. We conclude with a brief discussion of the ONCOBIOME initiative, which works with international partners to incorporate microbiome science into oncology workflows. By refining our understanding of gut-immune interactions and translating it into action, microbiome-informed oncology may unlock new therapeutic potential for patients previously resistant to immunotherapy.

> **中文摘要：**
> 肠道微生物组被认为是影响癌症患者对免疫检查点抑制剂（ICI）疗法反应的决定因素。然而，菌群失调定义不一致、生物标志物框架不完善以及机制理解有限，阻碍了微生物组科学的临床转化。在这篇综述中，我们综合了当前关于肠道微生物组成和功能如何影响ICI疗效的知识现状，重点阐述了相关性和因果性证据。我们讨论了基于α多样性或分类学丰度的计算方法，并主张采用更具功能和临床信息价值的模型，例如拓扑评分（TOPOSCORE）和其他源自机器学习的菌群失调指数。通过对来自数千名患者和健康对照的宏基因组数据集进行回顾性分析，我们研究了区分应答者与非应答者的微生物模式。我们还探讨了菌群失调如何扰乱免疫调节通路，包括胆汁酸代谢、肠道通透性和黏膜免疫调节。最后，我们评估了旨在纠正微生物组功能障碍的新兴治疗策略——包括饮食调整、细菌联合体和粪便微生物群移植——并描述了它们如何在多项临床试验中部署。我们以对ONCOBIOME计划的简要讨论作为结尾，该计划与国际合作伙伴合作，将微生物组科学整合到肿瘤学工作流程中。通过深化我们对肠道-免疫相互作用的理解并将其转化为行动，基于微生物组信息的肿瘤学可能为先前对免疫疗法抵抗的患者开启新的治疗潜力。

### 第二部分 AI 大师评价

本文旨在系统综述肠道菌群失调作为免疫检查点抑制剂（ICI）治疗抵抗风险因素的研究现状。其核心方法是通过整合相关性及因果性证据，并利用基于机器学习的功能性菌群失调指数（如TOPOSCORE）对大规模宏基因组数据进行回顾性分析，以揭示区分治疗应答者的微生物模式及免疫调节机制。本文的创新性在于超越了传统的α多样性分析，倡导更具临床信息价值的计算模型，并系统评估了多种基于菌群的治疗策略及其临床试验进展。然而，其局限性在于作为一篇综述，主要依赖于现有研究的综合，并未提供新的原始数据或机制验证，且文中提及的ONCOBIOME计划等转化应用仍处于早期阶段，其临床效用有待进一步证实。

---

## 7. 对RB1缺陷视网膜类器官中视网膜细胞状态转变的纵向分析揭示新生视锥前体细胞是人类视网膜母细胞瘤的最早细胞起源。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535675)
**期刊：** Cell death & disease
**PMID：** 41535675
**DOI：** 10.1038/s41419-025-08191-x

### 第一部分 原文与翻译

**英文原标题：** Longitudinal analysis of retinal cell state transitions in RB1-deficient retinal organoids reveals the nascent cone precursors are the earliest cell-origin of human retinoblastoma.

> **英文摘要：**
> All cancers arise from the malignant transformation of normal cells, yet their cells-of-origin remain challenging to identify due to the inability to directly observe dynamic changes in human tumors. Retinoblastoma (Rb), a malignant intraocular cancer, serves as a well-established model for investigating the molecular and cellular mechanisms underlying tumorigenesis. While the maturing cone precursors (CPs) have been proposed as the cellular origin of human Rb, it is unclear whether other retinal cell types are similarly sensitive to RB1 inactivation. In this study, we developed RB1-deficient human retinal organoids (ROs) models using RB1 or RB1 human induced pluripotent stem cells (hiPSCs). RB1 hiPSCs generated tumor cells that recapitulated key features of human Rb and formed serial orthotopic xenografts. Importantly, RB1 loss induced overproliferation of ATOH7 neurogenic retinal progenitor cells (nRPCs), which disrupted retinal development by generating ectopic dividing early-born retinal cells (retinal ganglion cells and CPs). Single-cell RNA sequencing analysis confirmed that ATOH7/RXRγ nascent CPs survived and ultimately drove Rb tumorigenesis. In contrast, monoallelic RB1 inactivation resulting in low pRB expression did not induce proliferation of nascent CPs, but only triggered overproliferation of nRPCs, leading to a retinocytoma-like phenotype. Finally, a potential therapeutic target for Rb was identified from multi-omics data and validated through knockdown experiment and a small-molecule inhibitor. Our findings demonstrate, for the first time, that nRPCs are the most sensitive cells to RB1 loss inducing abnormal proliferation of nascent retinal cells, while ATOH7 nascent CPs represent the earliest cellular origin of human Rb. These insights may facilitate the development of targeted therapies for Rb.

> **中文摘要：**
> 所有癌症都源于正常细胞的恶性转化，但由于无法直接观察人类肿瘤的动态变化，其起源细胞仍难以确定。视网膜母细胞瘤（Rb）是一种恶性眼内癌，是研究肿瘤发生分子和细胞机制的成熟模型。虽然成熟的视锥前体细胞（CPs）被认为是人类Rb的细胞起源，但尚不清楚其他视网膜细胞类型是否对RB1失活同样敏感。在本研究中，我们利用RB1或RB1人诱导多能干细胞（hiPSCs）开发了RB1缺陷的人视网膜类器官（ROs）模型。RB1 hiPSCs产生了能重现人类Rb关键特征并形成连续原位异种移植物的肿瘤细胞。重要的是，RB1缺失诱导了ATOH7神经源性视网膜祖细胞（nRPCs）的过度增殖，这通过产生异位分裂的早期视网膜细胞（视网膜神经节细胞和CPs）扰乱了视网膜发育。单细胞RNA测序分析证实，ATOH7/RXRγ新生CPs存活下来并最终驱动了Rb肿瘤发生。相比之下，导致pRB低表达的单等位基因RB1失活并未诱导新生CPs的增殖，而仅触发了nRPCs的过度增殖，导致视网膜细胞瘤样表型。最后，从多组学数据中确定了一个潜在的Rb治疗靶点，并通过敲低实验和一种小分子抑制剂进行了验证。我们的研究首次证明，nRPCs是对RB1缺失最敏感的细胞，能诱导新生视网膜细胞的异常增殖，而ATOH7新生CPs代表了人类Rb的最早细胞起源。这些发现可能有助于开发针对Rb的靶向疗法。

### 第二部分 AI 大师评价

本研究旨在利用RB1缺陷的人视网膜类器官模型，纵向解析视网膜母细胞瘤的细胞起源。通过结合基因编辑、类器官培养、单细胞测序及体内移植等技术，研究首次明确了ATOH7神经源性视网膜祖细胞（nRPCs）对RB1缺失最为敏感，并揭示了ATOH7/RXRγ标记的新生视锥前体细胞是Rb肿瘤发生的最早细胞起源，而非此前认为的成熟视锥前体。其创新性在于动态追踪了肿瘤起源的早期细胞状态转变，并区分了单等位与双等位RB1失活的不同表型。局限性在于类器官模型虽能模拟发育，但与体内完整肿瘤微环境仍存在差异，且所鉴定的治疗靶点需进一步临床前验证。

---

## 8. 揭示NPM1突变成人急性髓系白血病中具有预后意义的共突变模式——一项HARMONY研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535568)
**期刊：** Leukemia
**PMID：** 41535568
**DOI：** 10.1038/s41375-025-02851-9

### 第一部分 原文与翻译

**英文原标题：** Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

> **英文摘要：**
> NPM1-mutated (NPM1-mut) acute myeloid leukemia (AML) is generally associated with a more favorable outcome, although the presence of additional gene mutations can influence patient prognosis. We analyzed intensively-treated adult NPM1-mut AML patients included in the HARMONY Alliance database. A newly developed risk分类， which included combinations of co-mutations in FLT3-ITD, DNMT3A, IDH1/IDH2, and TET2 genes, was applied to a training cohort of NPM1-mut AML patients included in clinical trials (n = 1001), an internal validation cohort more representative of real-world settings (n = 762), and an external validation cohort enrolled in UK-NCRI trials (n = 585). The HARMONY classification considered 51.8% of the NPM1-mut AML training cohort patients as favorable, 24.8% as intermediate, and 23.4% as adverse risk, with median overall survival (OS) of 14.4, 2.2, and 0.9 years, respectively; p < 0.001), thereby reclassifying 42.7% of NPM1-mut patients into a different European LeukemiaNet (ELN) 2022 risk category. These results were confirmed both in an internal and external validation cohort. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) showed the highest benefit in the NPM1-mut adverse-risk subgroup. The HARMONY classification provides the basis for a refined genetic risk stratification for adult NPM1-mut AML with potential clinical impact on allo-HSCT decision-making.

> **中文摘要：**
> NPM1突变（NPM1-mut）急性髓系白血病（AML）通常与较好的预后相关，但额外的基因突变存在会影响患者预后。我们分析了纳入HARMONY联盟数据库的、接受强化治疗的成人NPM1-mut AML患者。一个新开发的风险分类（包含FLT3-ITD、DNMT3A、IDH1/IDH2和TET2基因的共突变组合）被应用于一个纳入临床试验的NPM1-mut AML患者训练队列（n=1001）、一个更能代表真实世界情况的内部验证队列（n=762）以及一个纳入英国NCRI试验的外部验证队列（n=585）。HARMONY分类将训练队列中51.8%的NPM1-mut AML患者判定为预后良好，24.8%为中等，23.4%为预后不良，其中位总生存期（OS）分别为14.4年、2.2年和0.9年（p<0.001），从而将42.7%的NPM1-mut患者重新划分到与欧洲白血病网（ELN）2022风险分类不同的类别中。这些结果在内部和外部验证队列中均得到证实。在首次完全缓解（CR1）期进行异基因造血干细胞移植（allo-HSCT）在NPM1-mut不良风险亚组中显示出最高的获益。HARMONY分类为成人NPM1-mut AML提供了精细化的遗传风险分层基础，可能对allo-HSCT的决策制定产生临床影响。

### 第二部分 AI 大师评价

本研究旨在通过分析共突变模式，优化NPM1突变AML的遗传风险分层。其核心方法是利用HARMONY联盟大数据，基于FLT3-ITD、DNMT3A、IDH1/IDH2和TET2的共突变组合，开发并验证了一个新的风险分类系统。主要发现是该分类能显著区分患者预后，并重新划分了近半数患者的ELN 2022风险类别，且明确了不良风险组患者从早期allo-HSCT中获益最大。其创新性在于整合多基因共突变模式，并在真实世界和外部队列中进行了稳健验证，为精准治疗决策提供了有力工具；局限性在于分析基于回顾性数据，且未纳入所有可能影响预后的分子标志物，其临床应用的普适性仍需前瞻性研究确认。

---

## 9. CFAP20从同向复制体的路径中拯救停滞的RNAPII。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535461)
**期刊：** Nature
**PMID：** 41535461
**DOI：** 10.1038/s41586-025-09943-7

### 第一部分 原文与翻译

**英文原标题：** CFAP20 salvages arrested RNAPII from the path of co-directional replisomes.

> **英文摘要：**
> Fine-tuning DNA replication and transcription is crucial to prevent collisions between their machineries. This is particularly important near promoters, where RNA polymerase II (RNAPII) initiates transcription and frequently arrests, forming R-loops. Arrested RNAPII can obstruct DNA replication, which often initiates near promoters. The mechanisms that rescue arrested RNAPII during elongation to avoid conflicts with co-directional replisomes remain unclear. Here, using genome-wide approaches and genetic screens, we identify CFAP20 as part of a protective pathway that salvages arrested RNAPII in promoter-proximal regions, diverting it from the path of co-directional replisomes. CFAP20-deficient cells accumulate R-loops near promoters, which leads to defects in replication timing and dynamics. These defects stem from accelerated replication-fork speeds that cause a secondary reduction in origin activity. Co-depletion of the Mediator complex or removal of R-loop-engaged RNAPII restores normal replication. Our findings suggest that transcription-dependent fork stalling in cis induces accelerated fork progression in trans, generating single-stranded DNA gaps. We propose that CFAP20 facilitates RNAPII elongation under high levels of Mediator-driven transcription, thereby preventing replisome collisions. This study provides a transcription-centred view of transcription-replication encounters, revealing how locally arrested transcription complexes propagate genome-wide replication phenotypes and defining CFAP20 as a key factor that safeguards genome stability.

> **中文摘要：**
> 精细调控DNA复制和转录对于防止两者机制间的碰撞至关重要。这在启动子附近尤为重要，因为RNA聚合酶II（RNAPII）在此处起始转录并频繁停滞，形成R环。停滞的RNAPII会阻碍DNA复制，而复制也常在启动子附近起始。在延伸过程中拯救停滞的RNAPII以避免与同向复制体发生冲突的机制尚不清楚。本研究通过全基因组方法和遗传筛选，鉴定出CFAP20是一个保护性通路的一部分，该通路在启动子邻近区域拯救停滞的RNAPII，使其偏离同向复制体的路径。CFAP20缺陷的细胞在启动子附近积累R环，导致复制时序和动力学缺陷。这些缺陷源于复制叉速度加快，进而引起复制起点活性的次级降低。共耗竭Mediator复合物或移除与R环结合的RNAPII可恢复正常复制。我们的发现表明，顺式转录依赖的复制叉停滞会诱导反式复制叉进程加速，从而产生单链DNA缺口。我们提出，CFAP20在高水平Mediator驱动的转录下促进RNAPII延伸，从而防止复制体碰撞。本研究提供了一个以转录为中心的转录-复制遭遇视角，揭示了局部停滞的转录复合物如何传播全基因组范围的复制表型，并将CFAP20定义为维护基因组稳定性的关键因子。

### 第二部分 AI 大师评价

本研究旨在阐明如何避免转录延伸过程中停滞的RNAPII与同向复制体发生冲突。通过全基因组方法和遗传筛选，作者发现CFAP20构成了一条保护性通路，能够拯救启动子邻近区域停滞的RNAPII，防止其阻碍复制。其核心创新在于揭示了局部转录停滞可通过改变复制叉动力学（加速）产生全基因组范围的复制表型，并提出了一个“顺式停滞诱导反式加速”的新机制模型。然而，CFAP20具体如何识别和“拯救”停滞RNAPII的分子细节，以及此通路在更广泛生理病理条件下的作用，仍有待进一步探索。

---

## 10. 循环代谢物、遗传学及生活方式因素与未来2型糖尿病风险的关系。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535386)
**期刊：** Nature medicine
**PMID：** 41535386
**DOI：** 10.1038/s41591-025-04105-8

### 第一部分 原文与翻译

**英文原标题：** Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes.

> **英文摘要：**
> The human metabolome reflects complex metabolic states affected by genetic and environmental factors. However, metabolites associated with type 2 diabetes (T2D) risk and their determinants remain insufficiently characterized. Here we integrated blood metabolomic, genomic and lifestyle data from up to 23,634 initially T2D-free participants from ten cohorts. Of 469 metabolites examined, 235 were associated with incident T2D during up to 26 years of follow-up, including 67 associations not previously reported across bile acid, lipid, carnitine, urea cycle and arginine/proline, glycine and histidine pathways. Further genetic analyses linked these metabolites to signaling pathways and clinical traits central to T2D pathophysiology, including insulin resistance, glucose/insulin response, ectopic fat deposition, energy/lipid regulation and liver function. Lifestyle factors-particularly physical activity, obesity and diet-explained greater variations in T2D-associated versus non-associated metabolites, with specific metabolites revealed as potential mediators. Finally, a 44-metabolite signature improved T2D risk prediction beyond conventional factors. These findings provide a foundation for understanding T2D mechanisms and may inform precision prevention targeting specific metabolic pathways.

> **中文摘要：**
> 人体代谢组反映了受遗传和环境因素影响的复杂代谢状态。然而，与2型糖尿病风险相关的代谢物及其决定因素仍未得到充分表征。本研究整合了来自十个队列、多达23,634名初始无T2D参与者的血液代谢组学、基因组学和生活方式数据。在检测的469种代谢物中，有235种在长达26年的随访期间与T2D发病相关，其中包括67种先前未报道过的关联，涉及胆汁酸、脂质、肉碱、尿素循环及精氨酸/脯氨酸、甘氨酸和组氨酸通路。进一步的遗传分析将这些代谢物与T2D病理生理学的核心信号通路和临床特征联系起来，包括胰岛素抵抗、葡萄糖/胰岛素反应、异位脂肪沉积、能量/脂质调节和肝功能。生活方式因素——特别是体力活动、肥胖和饮食——在T2D相关代谢物与非相关代谢物中解释了更大的变异，并揭示出特定代谢物作为潜在介导者。最后，一个包含44种代谢物的特征谱在传统因素之外改善了T2D风险预测。这些发现为理解T2D机制奠定了基础，并可能为针对特定代谢通路的精准预防提供信息。

### 第二部分 AI 大师评价

本研究通过大规模多组学数据整合，系统揭示了循环代谢物与2型糖尿病发病风险的前瞻性关联。其核心创新在于不仅识别了大量新关联代谢物，还通过遗传分析将其锚定于关键的病理生理通路，并量化了生活方式因素对代谢物的影响，从而构建了连接暴露、代谢中间表型与疾病终点的桥梁。研究提出的44-代谢物特征谱为超越传统风险因素的精准预测提供了工具。局限性在于其发现主要基于观察性数据，因果关系和具体介导机制有待实验验证，且代谢物谱的临床应用可行性需在更广泛人群中进一步评估。

---

## 11. 6-磷酸葡萄糖酸脱氢酶促进肿瘤相关单核髓源性抑制细胞的线粒体融合与免疫抑制功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535266)
**期刊：** Nature communications
**PMID：** 41535266
**DOI：** 10.1038/s41467-025-68102-8

### 第一部分 原文与翻译

**英文原标题：** 6-Phosphogluconate dehydrogenase promotes mitochondrial fusion and immune suppression in tumor-associated monocytic suppressor cells.

> **英文摘要：**
> The mechanisms underlying the metabolic adaptation of myeloid cells within the tumor microenvironment remain incompletely understood. Here, we identify 6-phosphogluconate dehydrogenase (6PGD), a rate-limiting enzyme in the pentose phosphate pathway (PPP), as an important regulator of monocytic-myeloid derived suppressor cell (M-MDSC) function. Our findings reveal that tumor M-MDSCs upregulate 6PGD expression via IL-6/STAT3 signaling. Blocking 6PGD, using either genetic or pharmacological approaches, impairs the immunosuppressive function of M-MDSCs and suppresses tumor growth. Mechanistically, 6PGD inhibition leads to the accumulation of its substrate, 6-phosphogluconate (6PG), within M-MDSCs, activates the JNK1-IRS1 and PI3K-AKT-pDRP1 signaling pathways, leading to mitochondrial fragmentation and elevated mitochondrial reactive oxygen species (ROS). This metabolic shift drives M-MDSCs toward an M1-like proinflammatory phenotype. Furthermore, 6PGD blockade synergizes with anti-PD-1 immunotherapy in a preclinical tumor model, substantially improving therapeutic outcomes. Our data reveals 6PGD as a possible therapeutic target to disrupt M-MDSC function and improve cancer immunotherapy outcomes.

> **中文摘要：**
> 髓系细胞在肿瘤微环境中的代谢适应机制仍未完全阐明。本研究将磷酸戊糖途径的限速酶——6-磷酸葡萄糖酸脱氢酶（6PGD）鉴定为单核髓源性抑制细胞（M-MDSC）功能的重要调节因子。我们的发现表明，肿瘤M-MDSCs通过IL-6/STAT3信号通路上调6PGD表达。通过遗传学或药理学方法阻断6PGD，会损害M-MDSCs的免疫抑制功能并抑制肿瘤生长。从机制上讲，抑制6PGD导致其底物6-磷酸葡萄糖酸（6PG）在M-MDSCs内积累，激活JNK1-IRS1和PI3K-AKT-pDRP1信号通路，从而导致线粒体碎片化和线粒体活性氧（ROS）水平升高。这种代谢转变驱动M-MDSCs向M1样促炎表型分化。此外，在临床前肿瘤模型中，阻断6PGD与抗PD-1免疫疗法具有协同作用，显著改善了治疗效果。我们的数据揭示了6PGD是破坏M-MDSC功能、改善癌症免疫治疗效果的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探索肿瘤微环境中髓系免疫抑制细胞（M-MDSCs）代谢调控的新机制。通过结合遗传学和药理学方法，研究发现磷酸戊糖途径关键酶6PGD受IL-6/STAT3信号上调，并通过其底物6PG的积累，激活下游信号通路，调控线粒体动力学与ROS水平，从而决定M-MDSCs的免疫抑制功能。其创新性在于将经典代谢酶6PGD的功能与线粒体形态及免疫表型转换直接联系起来，并提出了靶向6PGD可增强抗PD-1疗法疗效的新策略。局限性在于研究主要基于临床前模型，其转化至人体的有效性与安全性仍需进一步验证。

---

## 12. 多中心多组学整合预测甲状腺髓样癌的个体化预后。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535264)
**期刊：** Nature communications
**PMID：** 41535264
**DOI：** 10.1038/s41467-025-67533-7

### 第一部分 原文与翻译

**英文原标题：** Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.

> **英文摘要：**
> Medullary thyroid carcinoma (MTC) is a rare, aggressive neuroendocrine tumor with limited treatment options and frequent recurrence. Comprehensive recurrence risk stratification remains lacking. Here, we profile 482 MTC samples from 452 patients across ten Chinese clinical centers, identifying 10,092 proteins and mutations in 87.0% of patients. Clinically, MTC grading, concurrent papillary thyroid carcinoma, and lymph node metastasis are significant recurrence risk factors, whereas at the genetic level, RET M918T and RET S891A mutations are correlated with high recurrence risk in sporadic and hereditary MTC, respectively. Ubiquitinomics show downregulated E3 ligases CUL4B and TRIM32 are associated with structural recurrence. We define three molecular subtypes with distinct outcomes and present an integrative machine learning model combining clinical, genomic, and proteomic features, validated in an independent test dataset of 105 patients and a published dataset. This multi-center, multi-omics study enhances the understanding of MTC heterogeneity and facilitates personalized patient management.

> **中文摘要：**
> 甲状腺髓样癌（MTC）是一种罕见、侵袭性的神经内分泌肿瘤，治疗选择有限且易复发。目前仍缺乏全面的复发风险分层。本研究对来自中国十个临床中心的452名患者的482份MTC样本进行了分析，鉴定了10,092种蛋白质，并在87.0%的患者中发现了突变。在临床层面，MTC分级、并发甲状腺乳头状癌和淋巴结转移是显著的复发风险因素；而在基因层面，RET M918T和RET S891A突变分别与散发性和遗传性MTC的高复发风险相关。泛素化组学分析显示，下调的E3连接酶CUL4B和TRIM32与结构性复发相关。我们定义了三种具有不同预后的分子亚型，并提出了一个整合临床、基因组和蛋白质组学特征的机器学习模型，该模型在一个包含105名患者的独立测试数据集和一个已发表数据集中得到了验证。这项多中心、多组学研究加深了对MTC异质性的理解，并有助于实现个体化的患者管理。

### 第二部分 AI 大师评价

本研究是一项针对罕见肿瘤甲状腺髓样癌（MTC）的大规模、多中心、多组学整合分析。其核心目的是通过整合临床、基因组、蛋白质组及泛素化组学数据，建立个体化的预后预测模型。研究亮点在于纳入了来自中国十个中心的较大样本量，并首次在MTC中应用了泛素化组学分析，发现了新的复发相关分子标志物（如CUL4B、TRIM32）。创新性体现在定义了新的分子亚型并构建了跨组学的机器学习预测模型，为MTC的精准分层管理提供了有力工具。局限性在于摘要中未提及模型的具体性能指标（如AUC值），且所有样本均来自中国人群，其结论的普适性有待在其他人群中进一步验证。

---

## 13. TRIP13通过维持HAT1稳定性促进CD4+Foxp3+调节性T细胞的扩增与免疫抑制功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535263)
**期刊：** Cell death & disease
**PMID：** 41535263
**DOI：** 10.1038/s41419-025-08214-7

### 第一部分 原文与翻译

**英文原标题：** TRIP13 promotes the expansion and immunosuppression of CD4Foxp3 regulatory T cells by sustaining HAT1 stability.

> **英文摘要：**
> There is compelling evidence that TNF preferentially activates and expands CD4Foxp3 regulatory T cells (Tregs) through TNFR2. However, the precise mechanisms underlying TNF-TNFR2 pathway-mediated Treg proliferation remain to be fully elucidated. In this study, using RNA-seq profiling of TNFR2 and TNFR2-deficient Treg cells, we identified that Trip13 is required for promoting TNF-TNFR2 pathway-mediated Treg expansion. Mechanistically, TRIP13 inhibited UBE4A-mediated ubiquitination degradation of HAT1 by directly binding to HAT1, thereby competing with UBE4A and promoting Treg expansion. In addition, TRIP13's ATPase activity was essential for its binding to HAT1, which promoted Treg expansion by increasing Foxp3 expression. In a mouse colitis model, TRIP13 overexpression markedly alleviated colon inflammation by enhancing Treg expansion, an effect that was reversed by HAT1 knockdown. Conversely, genetic ablation of TRIP13 substantially reversed the effects induced by HAT1 overexpression, including enhanced Treg expansion and attenuation of colitis. These findings illustrate the TRIP13/HAT1 axis-mediated mechanism for TNF-TNFR2-induced Treg expansion and indicate that targeting TRIP13 may offer therapeutic potential for autoimmune and inflammatory diseases.

> **中文摘要：**
> 有充分证据表明，TNF通过TNFR2优先激活并扩增CD4+Foxp3+调节性T细胞。然而，TNF-TNFR2通路介导的Treg增殖的确切机制尚未完全阐明。在本研究中，通过对TNFR2+和TNFR2缺陷型Treg细胞进行RNA-seq分析，我们发现Trip13是促进TNF-TNFR2通路介导的Treg扩增所必需的。从机制上讲，TRIP13通过直接结合HAT1，抑制了UBE4A介导的HAT1泛素化降解，从而与UBE4A竞争并促进Treg扩增。此外，TRIP13的ATP酶活性对其结合HAT1至关重要，并通过增加Foxp3表达来促进Treg扩增。在小鼠结肠炎模型中，TRIP13过表达通过增强Treg扩增显著减轻了结肠炎症，而这一效应可被HAT1敲低所逆转。相反，TRIP13的基因缺失在很大程度上逆转了HAT1过表达诱导的效应，包括增强的Treg扩增和结肠炎的减轻。这些发现阐明了TRIP13/HAT1轴介导的TNF-TNFR2诱导Treg扩增的机制，并表明靶向TRIP13可能为自身免疫性和炎症性疾病提供治疗潜力。

### 第二部分 AI 大师评价

本研究旨在阐明TNF-TNFR2通路促进调节性T细胞扩增的具体分子机制。研究团队通过RNA-seq筛选并结合功能验证，发现TRIP13是关键分子，其通过依赖ATP酶活性直接结合并稳定HAT1，拮抗UBE4A介导的降解，从而上调Foxp3表达并驱动Treg扩增。创新性地揭示了TRIP13/HAT1这一全新的调控轴，并在小鼠结肠炎模型中证实了其功能与治疗潜力。然而，研究主要基于动物模型和细胞实验，TRIP13在人体自身免疫病中的具体作用及靶向治疗的可行性仍需进一步临床前和临床研究验证。

---

## 14. Dysadherin/碳酸酐酶9轴塑造酸性肿瘤微环境以促进结直肠癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535258)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41535258
**DOI：** 10.1038/s41392-025-02543-x

### 第一部分 原文与翻译

**英文原标题：** The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression.

> **英文摘要：**
> The tumor microenvironment (TME) plays a central role in cancer progression and metastasis. A key feature of the TME is extracellular acidity, which promotes disease progression, immune evasion, and drug resistance. Tumor acidity is increasingly recognized as a critical factor in cancer development and a negative prognostic indicator. Here, we demonstrate that the membrane glycoprotein dysadherin promotes colorectal cancer (CRC) malignancy by modulating TME acidity. Comprehensive bioinformatics and pathological analyses of CRC patient samples revealed that increased tumor acidity is a hallmark of CRC progression and strongly correlates with high expression of dysadherin. Functional studies confirmed that dysadherin enhances malignant traits, particularly under acidic conditions. Mechanistically, dysadherin activates the integrin/FAK/STAT3 signaling pathway, leading to the upregulation of carbonic anhydrase 9 (CA9). CA9 facilitates proton export, contributing to extracellular acidification while maintaining intracellular pH homeostasis, thereby enabling cancer cells to survive and thrive in acidic environments. In a murine liver metastasis model, dysadherin deletion impaired cellular adaptation to the acidic TME and markedly attenuated metastatic colonization, whereas restoring CA9 expression effectively rescued metastatic potential. Overall, our findings identify the dysadherin/CA9 axis as a potential therapeutic target in CRC and provide new insights into how tumors exploit acidosis to drive malignant development and progression.

> **中文摘要：**
> 肿瘤微环境（TME）在癌症进展和转移中起着核心作用。TME的一个关键特征是细胞外酸性，它促进疾病进展、免疫逃逸和耐药性。肿瘤酸性日益被认为是癌症发展的关键因素和不良预后指标。本文中，我们证明膜糖蛋白dysadherin通过调节TME酸性来促进结直肠癌（CRC）的恶性进展。对CRC患者样本的综合生物信息学和病理学分析表明，肿瘤酸度增加是CRC进展的标志，并且与dysadherin的高表达密切相关。功能研究证实，dysadherin增强了恶性特征，尤其是在酸性条件下。从机制上讲，dysadherin激活整合素/FAK/STAT3信号通路，导致碳酸酐酶9（CA9）上调。CA9促进质子外排，有助于细胞外酸化，同时维持细胞内pH稳态，从而使癌细胞能够在酸性环境中生存和增殖。在小鼠肝转移模型中，敲除dysadherin损害了细胞对酸性TME的适应能力，并显著减弱了转移定植，而恢复CA9表达则有效挽救了转移潜能。总之，我们的研究结果确定了dysadherin/CA9轴是CRC的潜在治疗靶点，并为肿瘤如何利用酸中毒驱动恶性发展和进展提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明dysadherin如何通过调控肿瘤微环境（TME）酸性促进结直肠癌（CRC）进展。研究综合运用了生物信息学、病理学分析、功能实验及小鼠转移模型，方法系统。核心发现是揭示了dysadherin通过激活整合素/FAK/STAT3通路上调CA9，从而驱动TME酸化并促进肿瘤恶性表型的新机制。其创新性在于将膜蛋白dysadherin与TME酸度调控直接联系起来，并明确了其下游信号轴，为靶向肿瘤酸中毒提供了新的潜在靶点。局限性在于摘要未提及该轴在人体内的治疗干预效果或与其他促癌通路的交叉对话，其临床转化潜力有待进一步验证。

---

## 15. 黑色素瘤中NOS1表达诱导的IRF7 S-亚硝基化抑制抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535256)
**期刊：** Cell death & disease
**PMID：** 41535256
**DOI：** 10.1038/s41419-025-08201-y

### 第一部分 原文与翻译

**英文原标题：** S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity.

> **英文摘要：**
> Endogenous nitric oxide (NO) produced by nitric oxide synthases (NOSs) plays an important immunosuppressive role in the tumor microenvironment. In melanoma, NOS1 expression increases with tumor progression and correlates with tumor immune escape through the inhibition of type I interferon (IFN) signaling. However, the immune regulatory role and related mechanisms of NOS1, as well as its impacts on immune therapies such as immune checkpoint blockade (ICB) in melanoma, remain unclear. Here, we found that NOS1 expression induces IRF7 modification by S-nitrosylation at the C435 site in mice (C481 in humans), which functionally promoted tumor growth in mouse models. Mechanistically, IRF7-C435-SNO inhibited IFNβ transcription under PRR signal activation, leading to a disorder in the initiation of the type I interferon response in melanoma cells. In a melanoma mouse model, IRF7-C435-SNO decreased the infiltration and activation of CD8 + T cells in the tumor microenvironment by reducing antigen presentation processes in tumor cells and inhibiting the maturation of DC1. Clinically, high expression of NOS1 correlated with poor survival prognosis and resistance to ICB anti-tumor therapies in melanoma cases with less immune cell infiltration. Our study suggests that NOS1 expression in melanoma characterizes IFN-I signal disorders in response to innate immune stimulation through IRF7 s-nitrosylation. Targeting NOS1 signaling might be beneficial for overcoming immune therapeutically resistance, particularly in immune-cold melanoma phenotype.

> **中文摘要：**
> 一氧化氮合酶（NOSs）产生的内源性一氧化氮（NO）在肿瘤微环境中发挥重要的免疫抑制作用。在黑色素瘤中，NOS1的表达随肿瘤进展而增加，并通过抑制I型干扰素（IFN）信号传导与肿瘤免疫逃逸相关。然而，NOS1的免疫调节作用及相关机制，以及其对黑色素瘤中免疫检查点阻断（ICB）等免疫疗法的影响，仍不清楚。本研究发现，NOS1表达诱导IRF7在小鼠C435位点（人类为C481位点）发生S-亚硝基化修饰，该修饰在功能上促进了小鼠模型中的肿瘤生长。从机制上讲，IRF7-C435-SNO在PRR信号激活下抑制IFNβ的转录，导致黑色素瘤细胞中I型干扰素反应的启动发生紊乱。在黑色素瘤小鼠模型中，IRF7-C435-SNO通过减少肿瘤细胞的抗原呈递过程和抑制DC1的成熟，降低了肿瘤微环境中CD8+T细胞的浸润和活化。临床上，NOS1的高表达与免疫细胞浸润较少的黑色素瘤病例的不良生存预后和对ICB抗肿瘤疗法的耐药性相关。我们的研究表明，黑色素瘤中的NOS1表达通过IRF7的S-亚硝基化，表征了响应先天免疫刺激的IFN-I信号紊乱。靶向NOS1信号通路可能有助于克服免疫治疗耐药性，特别是在免疫“冷”型黑色素瘤表型中。

### 第二部分 AI 大师评价

本研究旨在阐明黑色素瘤中NOS1通过S-亚硝基化修饰IRF7以抑制抗肿瘤免疫的具体机制及其临床意义。研究采用小鼠模型、分子机制探索和临床数据分析相结合的方法，发现NOS1诱导的IRF7-C435-SNO修饰是抑制I型干扰素反应、削弱CD8+T细胞浸润并导致免疫检查点阻断（ICB）耐药的关键环节。其创新性在于首次揭示了NOS1-IRF7 S-亚硝基化轴作为连接肿瘤代谢与先天免疫信号紊乱的核心通路，为“免疫冷”型黑色素瘤提供了新的治疗靶点；局限性在于主要发现基于小鼠模型，其在人类黑色素瘤中的普适性及靶向该通路的具体策略仍需进一步临床验证。

---

## 16. 抑制PSMD1通过调控RTKN/β-catenin/PD-L1轴抑制肝细胞癌肿瘤进展并增强抗肿瘤免疫

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535254)
**期刊：** Cell death & disease
**PMID：** 41535254
**DOI：** 10.1038/s41419-025-08241-4

### 第一部分 原文与翻译

**英文原标题：** PSMD1 inhibition suppresses tumor progression and enhances antitumor immunity by modulating the RTKN/β-catenin/PD-L1 axis in hepatocellular carcinoma.

> **英文摘要：**
> Immunotherapy has emerged as a promising approach in the management of cancer. However, the suboptimal efficacy of immunotherapy monotherapy underscores the need to develop more effective combination strategies. In this study, we focused on PSMD1 to investigate its role and the molecular pathways by which it regulates the response to immunotherapy in hepatocellular carcinoma (HCC). In HCC, elevated PSMD1 levels are linked to associated with poor prognosis. PSMD1 was predominantly expressed in malignant epithelial cells. Tissue microarray results showed that PSMD1 was highly expressed in tumor tissues. Silencing PSMD1 suppressed HCC cell proliferation and promoted apoptosis in both in vitro and in vivo models. Additionally, PSMD1 suppression decreased PD-L1 expression, thereby enhancing the therapeutic efficacy of anti-PD-1 therapy. Mechanistically, publicly available single-cell RNA sequencing (scRNA-seq) datasets indicated that PSMD1 positively regulates β-catenin signaling. Silencing of PSMD1 decreased the expression of β-catenin pathway-associated proteins. Further analysis via mass spectrometry revealed that PSMD1 interacts with Rhotekin (RTKN) and suppresses its ubiquitination. Subsequent experiments revealed that RTKN enhances β-catenin expression through AKT phosphorylation, thereby increasing PD-L1 transcription. In summary, our findings demonstrate that PSMD1 regulates RTKN protein expression, whereas RTKN facilitates β-catenin expression via AKT phosphorylation. This mechanism contributes to HCC progression and the effectiveness of immunotherapy. The PSMD1/RTKN/β-catenin axis could serve as a promising therapeutic target for HCC.

> **中文摘要：**
> 免疫疗法已成为癌症治疗中一种前景广阔的方法。然而，免疫疗法单药治疗的疗效欠佳，凸显了开发更有效联合策略的必要性。在本研究中，我们聚焦于PSMD1，以探究其在肝细胞癌中的作用及其调控免疫疗法反应的分子通路。在肝细胞癌中，PSMD1水平升高与不良预后相关。PSMD1主要在恶性上皮细胞中表达。组织微阵列结果显示，PSMD1在肿瘤组织中高表达。在体外和体内模型中，沉默PSMD1均能抑制HCC细胞增殖并促进细胞凋亡。此外，抑制PSMD1降低了PD-L1的表达，从而增强了抗PD-1疗法的治疗效果。从机制上讲，公开可用的单细胞RNA测序数据集表明，PSMD1正向调节β-catenin信号通路。沉默PSMD1降低了β-catenin通路相关蛋白的表达。通过质谱分析进一步揭示，PSMD1与Rhotekin相互作用并抑制其泛素化。后续实验表明，RTKN通过AKT磷酸化增强β-catenin表达，从而增加PD-L1的转录。总之，我们的研究结果表明，PSMD1调控RTKN蛋白表达，而RTKN通过AKT磷酸化促进β-catenin表达。这一机制促进了HCC的进展并影响了免疫疗法的有效性。PSMD1/RTKN/β-catenin轴可能成为HCC一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探索PSMD1在肝细胞癌免疫治疗应答中的调控作用及分子机制。研究综合运用了临床样本分析、体内外功能实验、单细胞测序数据挖掘及质谱互作验证等多种方法，系统揭示了PSMD1通过稳定RTKN、激活AKT/β-catenin信号轴上调PD-L1表达，从而促进肿瘤进展并削弱免疫治疗效果的完整通路。其创新性在于首次将蛋白酶体调节亚基PSMD1与RTKN/β-catenin/PD-L1轴联系起来，为HCC的免疫联合治疗提供了新的潜在靶点。然而，摘要未提及该轴在人体其他肿瘤类型中的普适性，也未讨论靶向此通路可能产生的脱靶效应或毒性，这些是未来转化研究需要关注的潜在局限性。

---

## 17. 撤稿声明：抗内源性逆转录病毒抗体促进肺癌免疫治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535475)
**期刊：** Nature
**PMID：** 41535475
**DOI：** 10.1038/s41586-026-10104-7

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为《自然》期刊上关于抗内源性逆转录病毒抗体在肺癌免疫治疗中作用的文章的撤稿声明。撤稿行为本身表明原始研究可能存在无法通过勘误解决的根本性问题，如数据真实性、分析错误或结论无法重复等。这提醒科学界在解读和跟进相关发现时需保持审慎，并强调了研究可重复性和数据严谨性的极端重要性。

---

## 18. 泛素连接酶KLHL6驱动对CD8 T细胞功能障碍的抵抗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535474)
**期刊：** Nature
**PMID：** 41535474
**DOI：** 10.1038/s41586-025-09926-8

### 第一部分 原文与翻译

**英文原标题：** The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction.

> **英文摘要：**
> The multifaceted dysfunction of tumour-infiltrating T cells, including exhaustion and mitochondrial dysfunction, remains a major obstacle in cancer immunotherapy. Transcriptomic and epigenomic regulation of T cell dysfunction have been extensively studied, but the role of proteostasis in regulating these obstacles remains less defined. Here we combined computational analyses of atlases of T cell exhaustion and mitochondrial fitness with performed targeted in vivo CRISPR screens, which identified the E3 ubiquitin ligase KLHL6 as a dual-negative regulator of both T cell exhaustion and mitochondrial dysfunction. Mechanistically, KLHL6 expression promoted TOX poly-ubiquitination and subsequent proteasomal degradation, thereby attenuating the transition of progenitor exhausted T cells towards terminal exhaustion. Simultaneously, KLHL6 maintained mitochondrial fitness by constraining the excessive mitochondrial fission that occurs during chronic T cell receptor stimulation by means of post-translational regulation of the PGAM5-Drp1 axis. However, KLHL6 is naturally downregulated by T cell receptor ligation, mitigating its potentially beneficial ubiquitin ligase activities during exposure to chronic stimulation. Enforcing KLHL6 expression in T cells markedly improved efficacy and long-term persistence against tumours and during viral infections in vivo. These findings uncover KLHL6 as a multifunctional, clinically actionable target for cancer immunotherapy, and highlight the potential of modulating proteostasis and ubiquitin modification to improve immunotherapy.

> **中文摘要：**
> 肿瘤浸润T细胞的多方面功能障碍，包括耗竭和线粒体功能障碍，仍然是癌症免疫治疗的主要障碍。T细胞功能障碍的转录组和表观基因组调控已被广泛研究，但蛋白质稳态在调节这些障碍中的作用仍不明确。在此，我们结合对T细胞耗竭和线粒体健康图谱的计算分析，并进行了靶向体内CRISPR筛选，鉴定出E3泛素连接酶KLHL6是T细胞耗竭和线粒体功能障碍的双重负向调节因子。从机制上讲，KLHL6表达促进了TOX的多聚泛素化及其随后的蛋白酶体降解，从而减弱了祖耗竭T细胞向终末耗竭的转变。同时，KLHL6通过翻译后调控PGAM5-Drp1轴，限制了慢性T细胞受体刺激期间发生的过度线粒体分裂，从而维持了线粒体健康。然而，KLHL6在T细胞受体连接时会被自然下调，这削弱了其在慢性刺激暴露期间潜在有益的泛素连接酶活性。在T细胞中强制表达KLHL6显著提高了体内抗肿瘤和抗病毒感染的疗效及长期持久性。这些发现揭示了KLHL6作为一个多功能、临床可行的癌症免疫治疗靶点，并凸显了通过调节蛋白质稳态和泛素修饰来改善免疫治疗的潜力。

### 第二部分 AI 大师评价

本研究旨在探索T细胞功能障碍中蛋白质稳态的作用，并寻找新的治疗靶点。通过整合计算分析与体内CRISPR筛选，研究者创新性地将KLHL6鉴定为同时抑制T细胞耗竭和维持线粒体功能的关键负调控因子。其核心发现在于揭示了KLHL6通过降解转录因子TOX和调控PGAM5-Drp1轴，从表观遗传和细胞器功能两个层面协同抵抗功能障碍的双重分子机制。研究的创新性在于将蛋白质降解系统与T细胞命运和代谢直接关联，为克服免疫治疗耐药性提供了全新的、可干预的靶点，但研究也指出KLHL6在慢性刺激下的自然下调是其内在局限性，提示未来可能需要开发策略来维持或恢复其活性。

---

## 19. 多胺依赖性代谢屏蔽调控选择性剪接。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535471)
**期刊：** Nature
**PMID：** 41535471
**DOI：** 10.1038/s41586-025-09965-1

### 第一部分 原文与翻译

**英文原标题：** Polyamine-dependent metabolic shielding regulates alternative splicing.

> **英文摘要：**
> Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding.

> **中文摘要：**
> 代谢物是细胞稳态的核心。尽管人们非常强调其满足能量和生物合成需求的相关性，但代谢中间体也充当信号分子的功能。本研究证明，对细胞稳态至关重要的多胺（一类小的多聚阳离子）能够调控前体mRNA的选择性剪接过程。我们发现，抑制多胺合成会增加剪接体蛋白的磷酸化，同时伴随着细胞和组织中选择性剪接的紊乱。从机制上讲，分子建模结合生化分析揭示，多胺与U2小核核糖核蛋白SF3亚复合体中剪接因子的酸性可磷酸化基序结合，从而阻止上游激酶的作用。我们将多胺通过这种方式调控蛋白质磷酸化的分子过程称为代谢屏蔽。

### 第二部分 AI 大师评价

本研究旨在揭示多胺作为代谢物在基因表达调控中的新功能。通过结合分子建模、生化实验以及细胞和组织水平的表型分析，作者发现多胺通过物理性结合并“屏蔽”剪接因子的磷酸化位点，从而精细调控选择性剪接。这一发现创新性地提出了“代谢屏蔽”这一新概念，将基础代谢物与转录后调控直接联系起来，为理解代谢-表观遗传交叉对话提供了新范式。其局限性在于，研究主要聚焦于机制阐述，多胺代谢扰动在复杂生理或病理条件下的整体剪接组学后果及其功能意义有待进一步探索。

---

## 20. 语言模型引导的哺乳动物代谢物预测与发现。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535467)
**期刊：** Nature
**PMID：** 41535467
**DOI：** 10.1038/s41586-025-09969-x

### 第一部分 原文与翻译

**英文原标题：** Language model-guided anticipation and discovery of mammalian metabolites.

> **英文摘要：**
> Despite decades of study, large parts of the mammalian metabolome remain unexplored. Mass spectrometry-based metabolomics routinely detects thousands of small molecule-associated peaks in human tissues and biofluids, but typically only a small fraction of these can be identified, and structure elucidation of novel metabolites remains challenging. Biochemical language models have transformed the interpretation of DNA, RNA and protein sequences, but have not yet had a comparable impact on understanding small分子 metabolism. Here we present an approach that leverages chemical language models to anticipate the existence of previously uncharacterized metabolites. We introduce DeepMet, a chemical language model that learns from the structures of known metabolites to anticipate the existence of previously unrecognized metabolites. Integration of DeepMet with mass spectrometry-based metabolomics data facilitates metabolite discovery. We harness DeepMet to reveal several dozen structurally diverse mammalian metabolites. Our work demonstrates the potential for language models to advance the mapping of the mammalian metabolome.

> **中文摘要：**
> 尽管经过数十年的研究，哺乳动物代谢组的很大部分仍未得到探索。基于质谱的代谢组学常规检测到人体组织和生物体液中数千个与小分子相关的峰，但通常只有其中一小部分能够被鉴定，而新代谢物的结构解析仍然具有挑战性。生化语言模型已经改变了DNA、RNA和蛋白质序列的解释方式，但尚未对理解小分子代谢产生类似的影响。在此，我们提出了一种利用化学语言模型来预测先前未表征代谢物存在的方法。我们介绍了DeepMet，这是一个化学语言模型，它从已知代谢物的结构中学习，以预测先前未被识别的代谢物的存在。将DeepMet与基于质谱的代谢组学数据相结合，促进了代谢物的发现。我们利用DeepMet揭示了数十种结构多样的哺乳动物代谢物。我们的工作证明了语言模型在推进哺乳动物代谢组图谱绘制方面的潜力。

### 第二部分 AI 大师评价

本研究旨在利用化学语言模型预测和发现哺乳动物中未被表征的代谢物，以填补代谢组学研究的空白。其核心方法是开发了名为DeepMet的化学语言模型，该模型通过学习已知代谢物的结构来预测新代谢物，并与质谱数据整合以指导发现。研究成功揭示了数十种结构多样的新代谢物，证明了该方法的有效性。其创新性在于将自然语言处理技术成功应用于小分子化学空间探索，为代谢物发现提供了新范式；局限性在于模型预测的准确性仍需通过更多实验验证，且其发现范围受限于训练数据的化学多样性。

---

## 21. 微生物群诱导的T细胞可塑性实现免疫介导的肿瘤控制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535459)
**期刊：** Nature
**PMID：** 41535459
**DOI：** 10.1038/s41586-025-09913-z

### 第一部分 原文与翻译

**英文原标题：** Microbiota-induced T cell plasticity enables immune-mediated tumour control.

> **英文摘要：**
> Therapies that harness the immune system to target and eliminate tumour cells have revolutionized cancer care. Immune checkpoint blockade (ICB), which boosts the anti-tumour immune response by inhibiting negative regulators of T cell activation, is remarkably successful in a subset of cancer patients. Yet a significant proportion do not respond to treatment, emphasizing the need to understand factors influencing the therapeutic efficacy of ICB. The gut microbiota, consisting of trillions of microorganisms residing in the gastrointestinal tract, has emerged as a critical determinant of immune function and response to cancer immunotherapy, with several studies demonstrating association of microbiota composition with clinical response. However, a mechanistic understanding of how gut commensal bacteria influence the efficacy of ICB remains elusive. Here we use a gut commensal microorganism, segmented filamentous bacteria (SFB), which induces an antigen-specific T helper 17 (T17) cell effector program in the small intestine lamina propria (SILP), to investigate how colonization with this microbe affects the efficacy of ICB in restraining distal growth of tumours sharing antigen with SFB. We find that anti-programmed cell death protein 1 (PD-1) treatment effectively inhibits the growth of implanted SFB antigen-expressing melanoma only if mice are colonized with SFB. Through T cell receptor (TCR) clonal lineage tracing, fate mapping and peptide-major histocompatability complex (MHC) tetramer staining, we identify tumour-associated SFB-specific T helper 1 (T1)-like cells derived from the homeostatic T17 cells induced by SFB colonization in the SILP. These gut-educated ex-T17 cells produce high levels of the pro-inflammatory cytokines interferon (IFN)-γ and tumour necrosis factor (TNF) within the tumour microenvironment (TME), enhancing antigen presentation and promoting recruitment, expansion and effector functions of CD8 tumour-infiltrating cytotoxic lymphocytes and thereby enabling anti-PD-1-mediated tumour control. Conditional ablation of SFB-induced IL-17ACD4 T cells, precursors of tumour-associated T1-like cells, abolishes anti-PD-1-mediated tumour control and markedly impairs tumour-specific CD8 T cell recruitment and effector function within the TME. Our data, as a proof of principle, define a cellular pathway by which a single, defined intestinal commensal imprints T cell plasticity that potentiates PD-1 blockade, and indicate targeted modulation of the microbiota as a strategy to broaden ICB efficacy.

> **中文摘要：**
> 利用免疫系统靶向和清除肿瘤细胞的疗法已经彻底改变了癌症治疗。免疫检查点阻断疗法通过抑制T细胞活化的负向调节因子来增强抗肿瘤免疫反应，在一部分癌症患者中取得了显著成功。然而，仍有相当大比例的患者对治疗无反应，这凸显了理解影响ICB疗效因素的必要性。肠道微生物群由栖息于胃肠道的数万亿微生物组成，已成为免疫功能和癌症免疫治疗反应的关键决定因素，多项研究已证明微生物群组成与临床反应相关。然而，关于肠道共生细菌如何影响ICB疗效的机制性理解仍然缺乏。在此，我们使用一种肠道共生微生物——分节丝状菌，它能在小肠固有层诱导抗原特异性辅助性T细胞17效应程序，来研究该微生物定植如何影响ICB抑制表达SFB抗原的远端肿瘤生长的疗效。我们发现，只有在小鼠被SFB定植的情况下，抗程序性细胞死亡蛋白1治疗才能有效抑制植入的表达SFB抗原的黑色素瘤的生长。通过T细胞受体克隆谱系追踪、命运图谱和肽-主要组织相容性复合物四聚体染色，我们鉴定出肿瘤相关的SFB特异性辅助性T细胞1样细胞，它们来源于SFB定植在SILP中诱导的稳态T17细胞。这些经肠道“教育”的前T17细胞在肿瘤微环境中产生高水平的促炎细胞因子干扰素-γ和肿瘤坏死因子，从而增强抗原呈递，促进CD8肿瘤浸润性细胞毒性淋巴细胞的募集、扩增和效应功能，进而实现抗PD-1介导的肿瘤控制。条件性消融SFB诱导的IL-17A+ CD4+ T细胞（肿瘤相关T1样细胞的前体细胞），会消除抗PD-1介导的肿瘤控制，并显著损害TME内肿瘤特异性CD8 T细胞的募集和效应功能。我们的数据，作为原理性证明，阐明了一条细胞通路：一种明确的肠道共生菌通过印记T细胞可塑性来增强PD-1阻断的疗效，并指出靶向调节微生物群是扩大ICB疗效的一种策略。

### 第二部分 AI 大师评价

本研究旨在阐明特定肠道共生菌（SFB）通过塑造T细胞可塑性来增强免疫检查点阻断疗效的具体细胞机制。研究创新性地采用SFB定植小鼠模型，结合TCR谱系追踪、命运图谱等高分辨率技术，揭示了肠道诱导的T17细胞可转化为肿瘤微环境中的T1样效应细胞，从而增强抗肿瘤免疫应答。其核心发现是定义了一条从肠道菌群到系统性抗肿瘤免疫的清晰细胞通路，为通过靶向调控微生物群提高免疫治疗应答率提供了强有力的原理验证。然而，研究主要基于小鼠模型和单一菌种，其结论在人类复杂微生物群落和肿瘤异质性中的普适性仍需进一步验证。

---

## 22. 一种“无处可藏”机制确保piRNA指导的DNA甲基化得以完全实现。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535457)
**期刊：** Nature
**PMID：** 41535457
**DOI：** 10.1038/s41586-025-09940-w

### 第一部分 原文与翻译

**英文原标题：** A nowhere-to-hide mechanism ensures complete piRNA-directed DNA methylation.

> **英文摘要：**
> The mouse PIWI-interacting RNA (piRNA) pathway provides sustained anti-transposon immunity to the developing male germline by directing transposon DNA methylation. The first step in this process is the recruitment of SPOCD1 to young LINE1 loci. Thereafter, piRNA-mediated tethering of the PIWI protein MIWI2 (also known as PIWIL4) to the nascent transposon transcript recruits the DNA methylation machinery. The piRNA pathway needs to methylate all active transposon copies but how this is achieved remains unknown. Here we show that nuclear piRNA and de novo methylation factors are all euchromatic, exposing constitutive heterochromatin as a genomic blind spot for the piRNA pathway. We discover a 'nowhere-to-hide' mechanism that enables piRNA pathway-mediated LINE1 surveillance of the entire genome. We find that SPOCD1 directly interacts with the nuclear pore component TPR, which forms heterochromatin exclusion zones adjacent to nuclear pores. In fetal gonocytes undergoing piRNA-directed DNA methylation, TPR is found both at the nuclear periphery and throughout the nucleoplasm. We find that the SPOCD1-TPR interaction is required for complete non-stochastic piRNA-directed LINE1 methylation. The loss of the SPOCD1-TPR interaction results in a fraction of SPOCD1 and other chromatin-bound piRNA factors relocalizing to constitutive heterochromatin where they are no longer accessible to MIWI2 and the de novo methylation machinery. In summary, the piRNA pathway has co-opted TPR to guarantee that LINE1s are accessible to the piRNA and de novo methylation machineries.

> **中文摘要：**
> 小鼠PIWI互作RNA（piRNA）通路通过指导转座子DNA甲基化，为发育中的雄性生殖系提供持续的逆转录转座子免疫。该过程的第一步是SPOCD1被招募至年轻的LINE1位点。随后，piRNA介导的PIWI蛋白MIWI2（也称为PIWIL4）与新生转座子转录本的结合，招募了DNA甲基化复合体。piRNA通路需要甲基化所有活跃的转座子拷贝，但如何实现这一点尚不清楚。本文中，我们发现核内piRNA和从头甲基化因子均位于常染色质区，这揭示了组成型异染色质是piRNA通路的一个基因组盲区。我们发现了一种“无处可藏”机制，使得piRNA通路能够介导对整个基因组的LINE1进行监视。我们发现SPOCD1直接与核孔成分TPR相互作用，TPR在核孔附近形成了异染色质排斥区。在经历piRNA指导的DNA甲基化的胎儿性原细胞中，TPR同时存在于核周和整个核质中。我们发现SPOCD1-TPR相互作用是实现完全、非随机的piRNA指导的LINE1甲基化所必需的。SPOCD1-TPR相互作用的缺失导致一部分SPOCD1和其他染色质结合的piRNA因子重新定位到组成型异染色质区，在那里它们不再能被MIWI2和从头甲基化复合体所接近。总之，piRNA通路利用了TPR来确保LINE1能够被piRNA和从头甲基化复合体所接近。

### 第二部分 AI 大师评价

本研究旨在揭示piRNA通路如何克服基因组盲区，实现对所有活跃LINE1转座子拷贝的完全DNA甲基化。通过结合分子互作与细胞定位分析，作者发现SPOCD1与核孔蛋白TPR的相互作用是关键机制。该发现的核心创新在于阐明了一种“无处可藏”的主动监视机制：TPR形成的异染色质排斥区确保了piRNA通路因子能够有效接触并甲基化通常难以接近的基因组区域，从而保障了雄性生殖系基因组的完整性。研究未讨论该机制在其他转座子类型或不同发育阶段中的普适性，也未涉及TPR功能失调可能导致的表观遗传缺陷。

---

## 23. 癌症或可通过窃取线粒体来逃避免疫防御。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41535433)
**期刊：** Nature
**PMID：** 41535433
**DOI：** 10.1038/d41586-026-00123-9

### 第一部分 原文与翻译

**英文原标题：** Cancer might evade immune defences by stealing mitochondria.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题提出了一个新颖的假说，即癌细胞可能通过窃取免疫细胞或其他细胞的线粒体来增强自身功能并逃避免疫监视。这一观点将肿瘤代谢重编程与免疫逃逸机制直接联系起来，具有重要的理论创新性，可能为癌症治疗开辟新的靶点。然而，目前摘要信息缺失，无法评估其具体的研究方法、实验证据和结论的稳健性，这是当前信息下的主要局限性。

---

## 24. 循环游离DNA检测在肝细胞癌中的临床应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532983)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41532983
**DOI：** 10.1097/HEP.0000000000001676

### 第一部分 原文与翻译

**英文原标题：** Clinical utilization of testing for cell-free DNA in hepatocellular cancer.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death globally. HCCs are often diagnosed in advanced stages, and most patients are not eligible for curative treatments. Semiannual abdominal ultrasound with serum alpha-fetoprotein is the current recommended surveillance strategy; however, it has suboptimal sensitivity and implementation, thereby lowering its effectiveness for early-stage HCC detection. Further, post-treatment monitoring of HCC recurrence or progression is not tailored to tumor aggressiveness. These failures highlight critical unmet needs, which can be addressed by novel biomarkers that enable early detection and guide individualized surveillance and post-treatment follow-up for HCC, ultimately leading to improved outcomes in this disease. Cell-free DNA (cfDNA), consisting of small fragments of DNA released from tumor and normal cells into the bloodstream, reflects tumor-specific molecular alterations and has emerged as a promising non-invasive biomarker. This review summarizes recent advances in cfDNA applications in HCC, including risk stratification, early detection, prognostication, and minimal residual disease assessment. Among them, cfDNA has made the most progress in early detection. cfDNA assays, combined with clinical and serum parameters, demonstrate sensitivity non-inferior or superior to ultrasound for detecting early HCC, with larger phase 3 validation studies ongoing. In contrast, the use of cfDNA for risk stratification, prognostication, and minimal residual disease detection remains in the early stages of clinical development. Future multicenter studies with standardized methodologies and rigorous validation will be essential to translate cfDNA into routine clinical practice for the management of HCC.

> **中文摘要：**
> 肝细胞癌是全球癌症相关死亡的主要原因之一。肝细胞癌常在晚期才被诊断，且大多数患者不适合接受根治性治疗。目前推荐的监测策略是每半年进行一次腹部超声联合血清甲胎蛋白检测；然而，该策略的敏感性和实施效果均不理想，从而降低了其对早期肝细胞癌的检测效能。此外，对肝细胞癌复发或进展的术后监测并未根据肿瘤侵袭性进行个体化调整。这些不足凸显了关键的未满足需求，而能够实现早期检测并指导肝细胞癌个体化监测和术后随访的新型生物标志物可以解决这些问题，最终改善该疾病的预后。循环游离DNA由肿瘤细胞和正常细胞释放到血液中的小片段DNA组成，能反映肿瘤特异的分子改变，已成为一种有前景的无创生物标志物。本综述总结了cfDNA在肝细胞癌中应用的最新进展，包括风险分层、早期检测、预后判断和微小残留病评估。其中，cfDNA在早期检测方面取得的进展最大。cfDNA检测联合临床和血清参数，在检测早期肝细胞癌方面显示出不劣于或优于超声的敏感性，目前正在进行更大规模的3期验证研究。相比之下，将cfDNA用于风险分层、预后判断和微小残留病检测仍处于临床开发的早期阶段。未来采用标准化方法和严格验证的多中心研究，对于将cfDNA转化为肝细胞癌管理的常规临床实践至关重要。

### 第二部分 AI 大师评价

本文是一篇关于循环游离DNA在肝细胞癌中临床应用前景的综述。其核心目的是总结cfDNA作为一种新型液体活检标志物，在解决当前HCC早期诊断和个体化监测等关键临床挑战方面的潜力。文章方法上系统梳理了cfDNA在HCC风险分层、早期检测、预后评估及微小残留病监测等多个维度的应用进展。主要发现指出，cfDNA在早期检测领域进展最为显著，其联合临床指标已显示出优于或等同于传统超声的敏感性，但在其他应用场景仍处早期研发阶段。其创新性在于全面评估了cfDNA这一前沿技术从基础研究到临床转化的现状，而局限性则在于多数应用尚未完成大规模验证，标准化和临床转化是未来关键。

---

## 25. 伴大血管侵犯的肝细胞癌：梳理异质性证据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532981)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41532981
**DOI：** 10.1097/HEP.0000000000001679

### 第一部分 原文与翻译

**英文原标题：** Hepatocellular carcinoma with macrovascular invasion : Navigating heterogeneous evidence.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在探讨伴大血管侵犯的肝细胞癌这一临床难题。其核心目的是对当前存在的异质性临床证据进行系统性梳理和导航，以期为临床决策提供更清晰的参考。文章很可能通过文献综述或专家共识的方法，整合不同研究的结果。其创新性在于直面该领域证据不一致的挑战，并尝试构建一个整合性的解读框架。然而，由于摘要不可用，其具体的研究方法、关键发现以及潜在的局限性（如纳入研究的质量差异、结论的普适性等）尚不明确。

---

## 26. 循环肿瘤细胞预测对靶向DLL3的双特异性抗体Tarlatamab的应答

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532856)
**期刊：** Cancer discovery
**PMID：** 41532856
**DOI：** 10.1158/2159-8290.CD-25-1483

### 第一部分 原文与翻译

**英文原标题：** Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab.

> **英文摘要：**
> The bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope DLL3. Tarlatamab is effective in small cell lung cancer (SCLC), but clinical outcomes vary, and no biomarkers enable patient selection. Single-cell RNA sequencing of SCLC biopsies identifies heterogeneity in DLL3 expression, and analysis of circulating tumor cells (CTCs) distinguishes individual patients as predominantly DLL3Pos or DLL3Low. In a prospective cohort of 20 patients, pretreatment DLL3 expression on CTCs predicts tarlatamab clinical benefit (85% sensitivity, 100% specificity). Necrotic CTC clusters in blood accompany treatment-induced tumor lysis. Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression, but persistence of other targetable neuro-endocrine epitopes; in other patients, DLL3 is retained on CTCs, but accompanied by systemic markers of T cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance.

> **中文摘要：**
> 双特异性抗体tarlatamab能将T细胞募集至表达神经内分泌表位DLL3的癌症。Tarlatamab对小细胞肺癌有效，但临床结局存在差异，且尚无生物标志物可用于患者选择。对SCLC活检组织进行单细胞RNA测序，发现了DLL3表达的异质性；对循环肿瘤细胞的分析可将个体患者区分为主要呈DLL3阳性或DLL3低表达。在一个包含20名患者的前瞻性队列中，CTC上治疗前的DLL3表达可预测tarlatamab的临床获益（敏感性85%，特异性100%）。血液中的坏死性CTC簇伴随着治疗诱导的肿瘤溶解。对tarlatamab获得性耐药在某些病例中与DLL3表达缺失相关，但其他可靶向的神经内分泌表位持续存在；在其他患者中，CTC上仍保留DLL3表达，但伴随系统性T细胞功能障碍标志物。对DLL3阳性CTC的定量可识别出可能从tarlatamab中获益的患者，而纵向监测可在出现获得性耐药时指导治疗决策。

### 第二部分 AI 大师评价

本研究旨在探索CTC上DLL3表达作为tarlatamab治疗SCLC的预测与监测生物标志物。研究通过单细胞测序揭示肿瘤异质性，并前瞻性验证了CTC DLL3状态对疗效的预测价值，其敏感性与特异性均较高。创新性地将液体活检与靶向治疗应答及耐药机制动态关联，为个体化治疗提供了新工具。局限性在于样本量较小，且耐药机制存在异质性，需更大规模研究验证其普适性。

---

## 27. 不同胃癌发病率国家间肠上皮化生的突变特征与克隆性造血研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532847)
**期刊：** Cancer discovery
**PMID：** 41532847
**DOI：** 10.1158/2159-8290.CD-25-0778

### 第一部分 原文与翻译

**英文原标题：** Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence.

> **英文摘要：**
> UNLABELLED: Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer-a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host-microbe mucosal immunity.
> 
> SIGNIFICANCE: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.

> **中文摘要：**
> 无标签：肠上皮化生（IM）是一种与胃癌风险增加相关的癌前病变，而胃癌是一种发病率存在地域差异的致命恶性肿瘤。通过对来自六个国家的1500多份IM样本进行高深度靶向测序，鉴定出47个显著突变基因，包括与高危人群和较差预后相关的驱动基因（ARID1A）、KRAS/MAPK信号通路基因（KRAS、BRAF、MAP2K1、MAP3K1和MAP2K4）以及黏膜免疫改变相关基因（PIGR）。IM全基因组测序和DNA甲基化分析揭示，SBS17是区分IM与正常胃组织的特异性突变特征，与DNA晚期复制、基因组低甲基化和烟草暴露相关。除了上皮来源的体细胞突变外，我们观察到IM患者中克隆性造血（CH）水平升高，这与年龄、吸烟以及进展为胃癌的风险增加相关。存在CH扩增的患者同时表现出IM PIGR截短突变，并且口腔来源细菌在IM微环境中的定植增加，这表明CH可能通过调节宿主-微生物黏膜免疫来促进IM进展。
> 
> 意义：这项国际研究确定了IM中反复出现的驱动基因、IM特异性突变特征，以及与IM相关的免疫景观和微生物组的改变。我们的结果强调了非上皮性体细胞改变（CH）在IM进展为胃癌中的作用，为早期癌症检测和拦截提供了新的转化机会。

### 第二部分 AI 大师评价

本研究旨在揭示肠上皮化生（IM）这一胃癌前病变的分子特征及其与胃癌风险的关系。研究采用多国队列、高深度靶向测序、全基因组测序和甲基化分析等多组学方法，系统鉴定了IM的驱动基因、特异性突变特征SBS17，并创新性地发现克隆性造血（CH）在IM中水平升高且与进展风险相关。其核心创新在于将CH这一非上皮性体细胞改变与IM的免疫微环境和口腔菌群定植联系起来，为理解IM进展机制和开发早期干预策略提供了新视角。局限性在于研究主要基于关联分析，CH促进IM进展的具体分子机制仍需后续功能实验验证。

---

## 28. Abemaciclib不依赖于CDK4/6抑制的双重靶向：tau激酶与自噬

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532696)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41532696
**DOI：** 10.1002/advs.202513135

### 第一部分 原文与翻译

**英文原标题：** Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition.

> **英文摘要：**
> Alzheimer's disease (AD) is marked by progressive cognitive decline driven largely by tau pathology, yet disease-modifying therapies targeting tau remain limited. In this study, we re-evaluated abemaciclib, a clinically approved CDK4/6 inhibitor for breast cancer and uncovered its previously unrecognized therapeutic potential in AD via CDK4/6-independent mechanisms. Using the APP/MAPT double knock-in mouse model (dKI) and AD patient-derived brain organoids, we found that abemaciclib robustly ameliorates cognitive deficits and reduces neurodegeneration without altering amyloid burden or glial activation. Mechanistically, abemaciclib selectively inhibited key tau kinases, particularly Ca⁺/calmodulin-dependent protein kinase II (CaMKII) and glycogen synthase kinase 3β (GSK3β), independent of CDK4/6 inhibition, as confirmed by lentiviral knockdown experiments. Furthermore, abemaciclib enhanced autophagic flux and lysosomal activity, promoting clearance of pathological tau proteins. This dual modulation-suppression of tau phosphorylation and facilitation of degradation-highlights abemaciclib as a promising repurposed therapeutic for AD. Our findings establish a novel pharmacological profile for abemaciclib beyond its canonical role in cell cycle control, offering immediate translational potential for tau-targeted AD therapy.

> **中文摘要：**
> 阿尔茨海默病（AD）以进行性认知功能下降为特征，这主要由tau病理驱动，然而针对tau的疾病修饰疗法仍然有限。在本研究中，我们重新评估了已获批用于乳腺癌的CDK4/6抑制剂abemaciclib，并通过不依赖于CDK4/6的机制，揭示了其在AD中先前未被认识的治疗潜力。利用APP/MAPT双敲入小鼠模型（dKI）和源自AD患者的脑类器官，我们发现abemaciclib在不改变淀粉样蛋白负荷或胶质细胞活化的前提下，显著改善了认知缺陷并减少了神经退行性变。机制上，abemaciclib选择性地抑制了关键的tau激酶，特别是Ca⁺/钙调蛋白依赖性蛋白激酶II（CaMKII）和糖原合酶激酶3β（GSK3β），且不依赖于CDK4/6抑制，这通过慢病毒敲低实验得到证实。此外，abemaciclib增强了自噬流和溶酶体活性，促进了病理性tau蛋白的清除。这种对tau磷酸化的抑制和促进其降解的双重调节作用，凸显了abemaciclib作为一种有前景的AD老药新用疗法。我们的研究结果确立了abemaciclib超越其在细胞周期调控中经典作用的新药理学特征，为靶向tau的AD治疗提供了直接的转化潜力。

### 第二部分 AI 大师评价

本研究旨在探索已上市药物abemaciclib在阿尔茨海默病中的新治疗潜力。核心方法是利用APP/MAPT双敲入小鼠模型和AD患者来源的脑类器官进行表型验证，并结合慢病毒敲低等分子生物学手段阐明机制。研究发现，abemaciclib通过不依赖于CDK4/6的机制，一方面选择性抑制CaMKII和GSK3β等关键tau激酶以减少tau磷酸化，另一方面增强自噬-溶酶体通路以促进病理性tau清除，从而在动物模型中显著改善认知功能并减少神经退行性变。其创新性在于首次系统揭示了abemaciclib在AD中的双重作用机制，为药物再利用提供了强有力的理论依据，并具有直接的转化前景。局限性在于，研究主要基于临床前模型，其疗效和安全性在AD患者中的验证仍需后续临床试验来证实。

---

## 29. 机械感觉毛细胞中转导通道门控力的电调控。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532609)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41532609
**DOI：** 10.1002/advs.202509171

### 第一部分 原文与翻译

**英文原标题：** Electrical Control of the Transduction Channels' Gating Force in Mechanosensory Hair Cells.

> **英文摘要：**
> The inner ear's hair cells rely on mechanosensitive ion channels to convert vibrations of their hair bundles into electrical signals. The mechanical correlates of channel gating-the gating force and the gating swing-are fundamental determinants of hair-cell mechanosensitivity but are still poorly understood. Here we show that varying the electrical potential across the sensory hair-cell epithelium continuously modulates the gating force, by up to ±100%. Our observations also revealed an abrupt transition between states of weak and strong gating force at a threshold potential, so that strong gating forces associated to high mechanosensitivity are observed only when the calcium influx through the channels is large enough, but not too large. Gating-force changes, remarkably enough, were explained by the modulability of the gating swing, ranging from values comparable to the channel pore size to nearly tenfold larger. Gating-swing control is expected to underly the hair cell's ability to tune its mechanosensitivity to minute sound stimuli.

> **中文摘要：**
> 内耳毛细胞依赖机械敏感性离子通道，将其纤毛束的振动转换为电信号。通道门控的力学关联——门控力与门控摆动——是毛细胞机械敏感性的基本决定因素，但目前仍知之甚少。本文中，我们发现改变感觉毛细胞上皮两侧的电势，可以连续调节门控力，调节幅度高达±100%。我们的观察还揭示，在某一阈值电位处，门控力会在弱与强两种状态间发生突然转变，因此，只有当通过通道的钙离子内流足够大但又不过大时，才能观察到与高机械敏感性相关的强门控力。值得注意的是，门控力的变化可以通过门控摆动的可调节性来解释，其调节范围从与通道孔径相当到接近十倍之大。门控摆动的调控被认为是毛细胞能够将其机械敏感性微调到微弱声音刺激的基础。

### 第二部分 AI 大师评价

本研究旨在阐明毛细胞机械转导通道门控力的调控机制。通过改变毛细胞上皮的电势，研究者发现门控力可被连续且大幅度地调控，并存在一个依赖于钙离子内流的阈值电位，决定了高机械敏感性状态的出现。核心创新在于揭示了门控力变化的物理基础是门控摆动的可调性，这为理解毛细胞如何微调其机械敏感性以适应微弱声音刺激提供了新的力学模型。局限性在于研究主要基于实验观察和机制推断，对于门控摆动如何被电势和钙离子精确调控的具体分子构象变化，仍需进一步的结构与生物物理研究来阐明。

---

## 30. 分泌的外泌体诱导丝状伪足形成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532547)
**期刊：** eLife
**PMID：** 41532547
**DOI：** 10.7554/eLife.101673

### 第一部分 原文与翻译

**英文原标题：** Secreted exosomes induce filopodia formation.

> **英文摘要：**
> Filopodia are dynamic adhesive cytoskeletal structures that are critical for directional sensing, polarization, cell-cell adhesion, and migration of diverse cell types. Filopodia are also critical for neuronal synapse formation. While dynamic rearrangement of the actin cytoskeleton is known to be critical for filopodia biogenesis, little is known about the upstream extracellular signals. Here, we identify secreted exosomes as potent regulators of filopodia formation. Inhibition of exosome secretion inhibited the formation and stabilization of filopodia in both cancer cells and neurons and inhibited subsequent synapse formation by neurons. Rescue experiments with purified small and large extracellular vesicles (EVs) identified exosome-enriched small EVs (SEVs) as having potent filopodia-inducing activity. Proteomic analyses of cancer cell-derived SEVs identified the TGF-β family coreceptor endoglin as a key SEV-enriched cargo that regulates filopodia. Cancer cell endoglin levels also affected filopodia-dependent behaviors, including metastasis of cancer cells in chick embryos and 3D migration in collagen gels. As neurons do not express endoglin, we performed a second proteomics experiment to identify SEV cargoes regulated by endoglin that might promote filopodia in both cell types. We discovered a single SEV cargo that was altered in endoglin-KD cancer SEVs, the transmembrane protein Thrombospondin Type 1 Domain Containing 7A (THSD7A). We further found that both cancer cell and neuronal SEVs carry THSD7A and that add-back of purified THSD7A is sufficient to rescue filopodia defects of both endoglin-KD cancer cells and exosome-inhibited neurons. We also find that THSD7A induces filopodia formation through activation of the Rho GTPase, Cdc42. These findings suggest a new model for filopodia formation, triggered by exosomes carrying THSD7A.

> **中文摘要：**
> 丝状伪足是动态的黏附性细胞骨架结构，对于多种细胞类型的方向感知、极化、细胞间黏附和迁移至关重要。丝状伪足对于神经元突触形成也至关重要。虽然已知肌动蛋白细胞骨架的动态重排对丝状伪足生物发生至关重要，但对其上游的细胞外信号知之甚少。在此，我们发现分泌的外泌体是丝状伪足形成的有效调节因子。抑制外泌体分泌会抑制癌细胞和神经元中丝状伪足的形成和稳定，并抑制神经元随后的突触形成。使用纯化的小型和大型细胞外囊泡（EVs）进行的拯救实验发现，富含外泌体的小型EVs（SEVs）具有强大的丝状伪足诱导活性。对癌细胞来源SEVs的蛋白质组学分析鉴定出TGF-β家族共受体endoglin是调节丝状伪足的关键SEV富集货物。癌细胞的endoglin水平也影响了依赖丝状伪足的行为，包括癌细胞在鸡胚胎中的转移和在胶原凝胶中的3D迁移。由于神经元不表达endoglin，我们进行了第二次蛋白质组学实验，以鉴定受endoglin调控、可能促进两种细胞类型丝状伪足形成的SEV货物。我们发现了一个在endoglin敲低的癌细胞SEVs中发生改变的单一SEV货物，即跨膜蛋白Thrombospondin Type 1 Domain Containing 7A（THSD7A）。我们进一步发现，癌细胞和神经元的SEVs都携带THSD7A，并且添加纯化的THSD7A足以挽救endoglin敲低的癌细胞和外泌体抑制的神经元的丝状伪足缺陷。我们还发现THSD7A通过激活Rho GTP酶Cdc42来诱导丝状伪足形成。这些发现提出了一个由携带THSD7A的外泌体触发的丝状伪足形成新模型。

### 第二部分 AI 大师评价

本研究旨在探索调控丝状伪足形成的上游细胞外信号，揭示了外泌体及其关键货物蛋白在这一过程中的核心作用。研究通过结合功能抑制/拯救实验、囊泡分选和蛋白质组学分析，系统性地从癌细胞和神经元模型中鉴定出外泌体（SEVs）是有效的丝状伪足诱导因子，并进一步解析了其关键货物Endoglin和THSD7A的作用机制。其核心创新在于提出了一个由特定外泌体货物（THSD7A）介导、通过激活Cdc42来触发丝状伪足形成的普适性新模型，连接了癌症转移和神经发育两个重要生物学过程。然而，摘要未提及该模型在更广泛生理或病理环境下的验证，以及THSD7A的具体作用受体和下游信号通路的完整细节，这些可能是未来研究的方向。

---

## 31. 一种基于自组装蛋白纳米颗粒的抗SARS-CoV-2模块化疫苗平台。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532509)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41532509
**DOI：** 10.1002/advs.202513431

### 第一部分 原文与翻译

**英文原标题：** A Modular Vaccine Platform Against SARS-CoV-2 Based on Self-Assembled Protein Nanoparticles.

> **英文摘要：**
> The COVID-19 pandemic has underscored the urgent need for deployable vaccine platforms capable of rapidly responding to emerging and re-emerging variants of human coronaviruses. BP26, an outer membrane protein of the zoonotic bacterium Brucella, self-assembles into a highly ordered, barrel-like nanoparticle that can serve as a vaccine platform, demonstrating immunogenicity against the influenza virus and cancer when combined with specific antigens. Here, we expanded its versatility by incorporating the SpyTag/SpyCatcher pair, enabling modular and site-specific antigen conjugation via simple mixing. SpyCatcher was genetically fused to BP26, and SpyTag to the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, generating RBD-displaying BP26 nanoparticles (BP26-RBD). Immunization of mice with BP26-RBD elicited strong RBD-specific and neutralizing antibody responses and conferred protection against lethal SARS-CoV-2 challenge. This plug-and-play nanoparticle design supports antigen production in diverse expression systems, retains antigenic structure, and allows multivalent display, providing a cost-effective and rapidly adaptable strategy for next-generation vaccines targeting evolving viral threats.

> **中文摘要：**
> COVID-19大流行凸显了对能够快速应对新出现和再现的人类冠状病毒变种的可部署疫苗平台的迫切需求。BP26是一种人畜共患细菌布鲁氏菌的外膜蛋白，可自组装成高度有序的桶状纳米颗粒，可作为疫苗平台，当与特定抗原结合时，已证明对流感病毒和癌症具有免疫原性。在此，我们通过引入SpyTag/SpyCatcher配对扩展了其多功能性，实现了通过简单混合即可进行的模块化和位点特异性抗原偶联。SpyCatcher被基因融合到BP26上，SpyTag则被融合到严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的受体结合域（RBD）上，从而生成了展示RBD的BP26纳米颗粒（BP26-RBD）。用BP26-RBD免疫小鼠引发了强烈的RBD特异性和中和抗体反应，并赋予了对致死性SARS-CoV-2攻击的保护力。这种即插即用的纳米颗粒设计支持在不同表达系统中生产抗原，保留抗原结构，并允许多价展示，为针对不断演变的病毒威胁的下一代疫苗提供了一种经济高效且快速适应的策略。

### 第二部分 AI 大师评价

本研究旨在开发一种模块化、快速响应的疫苗平台以应对SARS-CoV-2等冠状病毒变种。其核心方法是将布鲁氏菌外膜蛋白BP26的自组装纳米颗粒特性与SpyTag/SpyCatcher共价连接系统相结合，实现了抗原（SARS-CoV-2 RBD）的位点特异性、模块化展示。研究发现，构建的BP26-RBD纳米颗粒疫苗在小鼠模型中能诱导强烈的特异性及中和抗体反应，并提供致死性攻击保护。该平台的创新性在于其“即插即用”的模块化设计，允许快速更换抗原、支持多价展示且成本效益高，为应对新发病毒威胁提供了灵活策略；然而，其局限性在于目前结果仅基于临床前小鼠模型，在人体中的安全性和有效性尚待验证，且针对不同变异株的广谱保护能力也需要进一步评估。

---

## 32. GlycoChat揭示胰腺癌肿瘤微环境中的聚糖-凝集素调控回路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41532420)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41532420
**DOI：** 10.1002/advs.202514735

### 第一部分 原文与翻译

**英文原标题：** GlycoChat Uncovers Glycan-Lect in Circuits in the Tumor Microenvironment of Pancreatic Cancer.

> **英文摘要：**
> Aberrant glycosylation is a hallmark of cancer progression, yet its functional implications within the tumor microenvironment (TME) remain poorly understood. Here, a single-cell glycomic profiling strategy was applied to tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), enabling the identification of cell-type-specific glycome signatures and their dynamic alterations during the transition from classical to basal-like cancer subtypes. To systematically decode glycan-mediated communication in the TME, an analytical framework termed GlycoChat was developed for mapping global glycan-lectin circuits at single-cell resolution. GlycoChat identified CLEC10A and SIGLEC3 as lectin receptors expressed on tumor-associated macrophages that interact with cancer cell surface glycans. Functional assays demonstrated that cancer cells promote differentiation of immunosuppressive macrophages and impair phagocytic activity through interactions with CLEC10A and SIGLEC3. This study establishes GlycoChat as a powerful tool for dissecting glycan-lectin circuits in complex TME and highlights glyco-immune checkpoints as potential targets for therapeutic intervention in PDAC.

> **中文摘要：**
> 异常糖基化是癌症进展的标志，但其在肿瘤微环境（TME）中的功能意义仍知之甚少。本研究对胰腺导管腺癌（PDAC）患者的肿瘤组织应用了单细胞糖组学分析策略，从而能够识别细胞类型特异性的糖组特征及其在从经典型向基底样亚型转变过程中的动态变化。为了系统解码TME中聚糖介导的通讯，我们开发了一个名为GlycoChat的分析框架，用于在单细胞分辨率下绘制全局聚糖-凝集素调控回路。GlycoChat鉴定出CLEC10A和SIGLEC3是肿瘤相关巨噬细胞上表达的凝集素受体，它们与癌细胞表面的聚糖相互作用。功能实验表明，癌细胞通过与CLEC10A和SIGLEC3的相互作用，促进了免疫抑制性巨噬细胞的分化并削弱了其吞噬活性。本研究确立了GlycoChat作为解析复杂TME中聚糖-凝集素回路的有力工具，并强调了糖免疫检查点作为PDAC治疗干预的潜在靶点。

### 第二部分 AI 大师评价

本研究核心目的是系统解析胰腺癌肿瘤微环境中聚糖-凝集素介导的细胞间通讯。其创新性在于开发了GlycoChat这一单细胞分辨率分析框架，实现了对复杂糖组-受体网络的全局性映射。关键发现是鉴定了巨噬细胞上的CLEC10A和SIGLEC3作为功能性糖免疫检查点，揭示了癌细胞通过此通路塑造免疫抑制微环境的新机制，为PDAC治疗提供了新靶点。局限性在于，研究主要基于关联分析和体外功能验证，其体内功能及靶向干预的疗效仍需后续实验深入探索。

---

## 33. 重建转移之旅：基于功能性循环肿瘤细胞和播散性肿瘤细胞的转化肿瘤学模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41530861)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41530861
**DOI：** 10.1186/s13046-025-03617-y

### 第一部分 原文与翻译

**英文原标题：** Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology.

> **英文摘要：**
> Metastatic progression, driven by the dissemination of circulating tumor cells (CTCs) through the bloodstream, remains the leading cause of cancer-related death. A rare subset of CTCs, characterized by tumor-initiating properties and phenotypic plasticity, plays a pivotal role in the formation of distant metastases. The ability of these cells to survive in the circulation, evade the immune surveillance, and establish secondary tumors underscores their biological significance. However, CTC extreme rarity and heterogeneity pose major challenges for their in-depth functional characterization. Disseminated tumor cells (DTCs) are cells that have extravasated and persist in distant organ niches, often in a dormant state, and represent a complementary and equally critical component of metastatic progression. Their capacity to remain quiescent for prolonged periods before reactivation highlights the need to study both CTCs and DTCs to fully understand metastasis initiation and relapse. Recent advances in CTC isolation and culture have led to the development of patient-derived CTC lines and CTC-derived xenograft animal models, offering unprecedented opportunities to investigate metastatic seeding, therapeutic resistance and tumor evolution. CTC- and DTC-based models provide valuable insights into the biology of CTCs from different cancer types, revealing key molecular drivers of metastasis formation and potential therapeutic targets. In this review, we summarize the state-of-the-art methodologies for establishing CTC- and DTC-based models and evaluate their contribution to understand tumor progression and response to treatments. We discuss the current challenges in generating and maintaining these models, including the influence of hypoxic conditions, enrichment strategies, and culture medium optimization. Then, we highlight their potential applications in precision oncology, particularly for biomarker discovery and for preclinical drug testing.

> **中文摘要：**
> 由循环肿瘤细胞（CTCs）通过血流播散驱动的转移进展，仍然是癌症相关死亡的主要原因。CTCs中一个罕见的亚群，具有肿瘤起始特性和表型可塑性，在远处转移灶的形成中起着关键作用。这些细胞在循环中存活、逃避免疫监视并建立继发性肿瘤的能力，突显了其生物学重要性。然而，CTC的极端稀有性和异质性对其深入的功能表征构成了重大挑战。播散性肿瘤细胞（DTCs）是已外渗并持续存在于远处器官微环境中的细胞，通常处于休眠状态，是转移进展中一个互补且同样关键的组成部分。它们在重新激活前能够长期保持静息的能力，凸显了需要同时研究CTCs和DTCs以充分理解转移的起始和复发。CTC分离和培养技术的最新进展，促进了患者来源的CTC细胞系和CTC来源的异种移植动物模型的发展，为研究转移定植、治疗耐药性和肿瘤进化提供了前所未有的机会。基于CTC和DTC的模型为不同癌症类型中CTC的生物学提供了宝贵的见解，揭示了转移形成的关键分子驱动因素和潜在的治疗靶点。在本综述中，我们总结了建立基于CTC和DTC模型的最先进方法，并评估了它们对理解肿瘤进展和治疗反应的贡献。我们讨论了当前在生成和维持这些模型方面面临的挑战，包括缺氧条件的影响、富集策略和培养基优化。然后，我们重点介绍了它们在精准肿瘤学中的潜在应用，特别是在生物标志物发现和临床前药物测试方面。

### 第二部分 AI 大师评价

本文旨在系统综述基于功能性循环肿瘤细胞（CTCs）和播散性肿瘤细胞（DTCs）的转化研究模型。其核心方法是总结CTC/DTC模型的构建技术（如患者来源细胞系、异种移植模型），并评估其在解析转移生物学、治疗耐药和肿瘤进化中的应用。主要发现是这些模型为揭示转移的关键分子驱动因素和潜在治疗靶点提供了宝贵平台，并有望应用于生物标志物发现和临床前药物测试。其创新性在于整合了CTCs（循环中）和DTCs（休眠中）两种互补模型，以更完整地“重建转移之旅”，但局限性在于模型构建本身仍面临细胞稀有性、异质性和培养条件优化等重大技术挑战。

---

## 34. 中枢神经系统淋巴瘤中CD19靶向嵌合抗原受体T细胞疗法失败的模式、危险因素及处理策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41530773)
**期刊：** Journal of hematology & oncology
**PMID：** 41530773
**DOI：** 10.1186/s13045-025-01761-8

### 第一部分 原文与翻译

**英文原标题：** Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.

> **英文摘要：**
> BACKGROUND: CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal salvage therapies remain unclear. METHODS: Clinical and radiological characteristics of CD19-CAR failure were therefore retrospectively defined in CNSL treated at Massachusetts General Hospital from 2018 to 2024. PD patterns were defined as local or distant. CNS-progression-free survival from CD19-CAR infusion (CNS-PFS1) and first subsequent progression (CNS-PFS2) were analyzed. RESULTS: CD19-CAR achieved a 60% overall response rate (45% complete (CR), 15% partial response) in 60 recurrent CNSL. Median CNS-PFS1 was 4 months with radiographic PD in 36 patients (local 23.3%; local and distant 16.7%; distant 20%). PD patterns were associated with prior CD19-CAR response: Distant relapse typically occurred after CR whereas local PD followed CD19-CAR refractory disease. Peripherally contrast enhancing CNSL (pCE) at CD19-CAR infusion correlated with refractory disease. Leptomeningeal involvement (LMD) was associated with recurrence after CR. On multivariable Cox regression, pCE (Hazard ratio [HR]: 2.75; 95%-Confidence interval [CI]: 1.08-6.68, p = 0.03) and LMD (HR: 2.72; CI: 1.20-6.25, p = 0.02) were independently associated with shorter CNS-PFS1. At progression, peripheral CD19-B-cell aplasia suggested CD19-CAR persistence in 93% of patients. Median CNS-PFS2 after CD19-CAR failure was one month. Salvage immune checkpoint inhibition, and lenalidomide with rituximab/tafasitamab yielded prolonged responses. CONCLUSIONS: This study identifies novel radiological risk factors for CD19-CAR failure in CNSL, namely pCE and LMD. Outcome in this setting is unfavorable and encouraging salvage treatments warrant prospective evaluation.

> **中文摘要：**
> 背景：CD19靶向嵌合抗原受体T细胞疗法（CD19-CAR）在中枢神经系统淋巴瘤（CNSL）中显示出令人鼓舞的疗效，但大多数患者最终出现疾病进展（PD）。其危险因素、进展模式以及最佳挽救治疗方案仍不明确。方法：本研究回顾性分析了2018年至2024年在麻省总医院接受治疗的CNSL患者中CD19-CAR失败的临床和影像学特征。将PD模式定义为局部或远处进展。分析了从CD19-CAR输注开始的中枢神经系统无进展生存期（CNS-PFS1）以及首次后续进展后的中枢神经系统无进展生存期（CNS-PFS2）。结果：在60例复发性CNSL患者中，CD19-CAR的总缓解率为60%（45%完全缓解（CR），15%部分缓解）。中位CNS-PFS1为4个月，36例患者出现影像学PD（局部23.3%；局部合并远处16.7%；远处20%）。PD模式与既往CD19-CAR的疗效相关：远处复发通常发生在CR之后，而局部PD则出现在CD19-CAR难治性疾病之后。CD19-CAR输注时存在外周对比增强的CNSL（pCE）与难治性疾病相关。软脑膜受累（LMD）与CR后复发相关。在多变量Cox回归分析中，pCE（风险比[HR]：2.75；95%置信区间[CI]：1.08-6.68，p=0.03）和LMD（HR：2.72；CI：1.20-6.25，p=0.02）均与较短的CNS-PFS1独立相关。在疾病进展时，93%的患者出现外周CD19+B细胞缺失，提示CD19-CAR持续存在。CD19-CAR失败后的中位CNS-PFS2为一个月。挽救性免疫检查点抑制剂治疗，以及来那度胺联合利妥昔单抗/他法西他单抗治疗产生了持久的缓解。结论：本研究确定了CNSL中CD19-CAR失败的新影像学危险因素，即pCE和LMD。在此情况下的预后不佳，而令人鼓舞的挽救治疗方案值得进行前瞻性评估。

### 第二部分 AI 大师评价

本研究旨在系统探索CNSL患者接受CD19-CAR-T治疗后失败的模式、危险因素及后续管理。研究采用单中心回顾性队列设计，通过分析临床与影像学特征，明确了局部与远处进展的不同模式及其与前期疗效的关联。核心发现是识别了pCE和LMD这两个独立的影像学危险因素，并观察到进展后CAR-T细胞可能持续存在，同时初步提示了免疫检查点抑制剂等挽救方案的潜力。其创新性在于首次系统描绘了CNSL中CAR-T失败的具体图景并提出了新的影像学生物标志物，但作为回顾性研究，其结论需在前瞻性队列中验证，且挽救治疗的有效性数据尚属初步观察。

---

## 35. 氧化代谢受损损害Rad51招募并增强PARP抑制剂在卵巢癌中的疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41530766)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41530766
**DOI：** 10.1186/s13046-026-03641-6

### 第一部分 原文与翻译

**英文原标题：** Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨氧化代谢受损对卵巢癌DNA损伤修复及PARP抑制剂疗效的影响。其核心方法可能是通过实验手段抑制肿瘤细胞的氧化代谢，观察其对同源重组修复关键蛋白Rad51招募的影响。研究发现，氧化代谢受损会损害Rad51的招募，从而削弱同源重组修复能力，进而增强了PARP抑制剂的合成致死效应。其创新性在于将细胞代谢状态（氧化代谢）与DNA修复效率和靶向治疗敏感性联系起来，为克服PARP抑制剂耐药提供了新思路；局限性在于摘要信息缺失，具体实验模型、代谢干预手段及体内外验证细节不明，结论的普适性有待进一步确认。

---

## 36. CD39基因多态性促使镰状细胞病患者发生肺血栓形成。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41530145)
**期刊：** Nature communications
**PMID：** 41530145
**DOI：** 10.1038/s41467-026-68396-2

### 第一部分 原文与翻译

**英文原标题：** CD39 polymorphism enables lung thrombosis in sickle cell disease.

> **英文摘要：**
> Sickle cell disease (SCD) is the most common monogenic-hemolytic disorder affecting people of African ancestry. Adenosine diphosphate (ADP) released following intravascular hemolysis activates platelets by stimulating purinergic receptors to promote thrombosis. Despite brisk intravascular hemolysis, which releases high levels of ADP into plasma, and evidence of platelet and hemostatic activation, it remains elusive why only a subset of SCD patients develop lung thrombosis. Using real-time in vivo lung microscopy, we report a surprising finding that humanized SCD mice are protected from ADP-induced lung thrombosis, which is secondary to the degradation of ADP by CD39 present in circulating extracellular vesicles released by the lung endothelium. ADP-induced platelet aggregation is also impaired in the blood of SCD patients with elevated levels of CD39 extracellular vesicles. CD39 polymorphism rs3176891A→G is associated with the incidence of lung thrombosis in SCD patients but not healthy humans of African ancestry. Remarkably, CD39 extracellular vesicles are fewer and ADP-induced platelet aggregation is higher in the blood of SCD patients with rs3176891G allele. This study identifies a novel extracellular vesicle-dependent mechanism preventing lung thrombosis in SCD and reveals how CD39 polymorphisms may impair this protection to increase the risk for lung thrombosis in a subset of SCD patients.

> **中文摘要：**
> 镰状细胞病（SCD）是影响非洲裔人群最常见的单基因溶血性疾病。血管内溶血后释放的二磷酸腺苷（ADP）通过刺激嘌呤能受体激活血小板，从而促进血栓形成。尽管存在活跃的血管内溶血（向血浆中释放高水平的ADP）以及血小板和凝血系统激活的证据，但为何只有一部分SCD患者会发生肺血栓形成仍不清楚。利用实时体内肺显微技术，我们报告了一个令人惊讶的发现：人源化SCD小鼠受到保护，免于发生ADP诱导的肺血栓形成，这归因于肺内皮释放的循环细胞外囊泡中存在的CD39对ADP的降解作用。在CD39细胞外囊泡水平升高的SCD患者血液中，ADP诱导的血小板聚集也受到抑制。CD39基因多态性rs3176891A→G与SCD患者肺血栓形成的发生率相关，但与非洲裔健康人群无关。值得注意的是，在携带rs3176891G等位基因的SCD患者血液中，CD39细胞外囊泡数量更少，而ADP诱导的血小板聚集更强。本研究鉴定了一种新的、依赖细胞外囊泡的机制，该机制在SCD中防止肺血栓形成，并揭示了CD39基因多态性如何可能损害这种保护作用，从而增加一部分SCD患者发生肺血栓形成的风险。

### 第二部分 AI 大师评价

本研究旨在探究镰状细胞病（SCD）患者中肺血栓形成风险存在个体差异的机制。研究团队结合了人源化小鼠模型的实时体内肺显微观察与SCD患者的血液样本分析，方法学上具有创新性。核心发现是：肺内皮来源的、携带CD39的细胞外囊泡通过降解ADP发挥保护作用，而CD39基因多态性（rs3176891G）会减少此类保护性囊泡，从而增加特定SCD患者的血栓风险。该研究创新性地揭示了细胞外囊泡在SCD血栓病理中的关键调节作用，并建立了基因型与表型之间的功能联系。局限性在于，研究主要基于动物模型和体外功能实验，其在人类疾病进程中的确切作用及作为临床生物标志物的潜力尚需更大规模的前瞻性队列研究验证。

---

速递结束，祝您工作愉快！